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ABSTRACT
While diet and sedentary lifestyle remain important factors in the development of
obesity, recent findings have shown the possible involvement of environmental
obesogens, chemicals that can disrupt homeostatic energy balance and increase
adiposity. Bisphenol A (BPA) is a compound used in the manufacturing of plastics as a
hardening agent and is ubiquitous in the environment due to its widespread use. BPA
has been shown to be an endocrine disruptor through its ability to mimic estrogen,
which is now known to play important roles in adipose tissue growth and metabolism. In
fact, a small but compelling number of studies have shown that mice exposed to BPA in
utero or postnatally are fatter as adults.
We hypothesized that BPA exposure exerts effects on adipose tissue, promoting
adipogenesis and inflammation, and altering energy homeostasis in a manner that
promotes obesity. We tested our hypothesis using both in vitro and in vivo models.
First, we found that low concentrations of BPA increased the expression of the
inflammatory genes, Il-6 and Tnfa, approximately 1.5-3.0 fold in mouse adipose tissue
explants. We also found a 3-fold increase in the expression of the lipogenic gene,
Fasn. BPA also altered the adipose tissue metabolism, increasing the levels of a
number of glycolytic and TCA cycle metabolites, suggesting that BPA may disrupt
energy homeostasis. We also found that BPA exposure increased proliferation of
mesenchymal stem cells approximately 1.2-fold, which are potential adipocyte
precursors. The study was expanded using two different strains of mice, C57BL/6 and
DBA/2J, chronically exposing them to BPA through drinking water for six weeks. A
v

moderate concentration of BPA increased the perigonadal fat pad mass in males. This
increase in adiposity was associated with adipocyte hypertrophy and decreased serum
adiponectin levels. There were also changes in the expression of some genes with
BPA treatment, including a 1.4-fold increase in Leptin and decreases in some
Cytochrome P450 genes; however the genes differentially expressed were different
between the two strains. Our results suggest that childhood exposure to low doses of
BPA, in lieu of any developmental exposure, may contribute to childhood obesity.
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CHAPTER I
LITERATURE REVIEW
Obesity and the Role of Adipose Tissue
The incidence of obesity has increased dramatically over the past 25 years.
More than 300 million people, worldwide, are obese, and the majority of developed and
rapidly developing countries have seen dramatic increases in obesity (James, 2004,
James et al., 2001). Obesity occurs when body fat becomes excessive and adversely
affects other organs such as the heart and liver. This obesity epidemic has garnered
much attention in recent years due to the overwhelming burden that obesity and its
comorbidities (diabetes, cardiovascular disease, cancer, etc.) have put on the
healthcare system. The estimated annual healthcare cost for obesity was 147 billion
dollars in 2008, or up to 9.1% of annual healthcare cost compared to 6.5% in 1998
(Finkelstein et al., 2009). Recently, there was passage of a new healthcare bill in the
United States. During this debate, there was a fair amount of discussion about ways to
cut cost. Curbing the obesity trends in this country would certainly be one solution to
reduce healthcare spending.
Obesity occurs as a result of a disruption of the body’s energy homeostasis.
When caloric intake far exceeds energy expenditure, excess energy is stored as fat in
adipose tissue. The disruption of the body’s energy balance equation has become
inherently easier to incur as a result of the modern Western lifestyle. The average
American diet consists of energy dense meals that have high amounts of fat, sugar, and
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sodium. Many of the factory and industrial jobs that required physical labor have been
replaced with office jobs, which have led many Americans to become much more
sedentary. The combination of diet and inactivity has created an obesogenic
environment in the United States and other western countries, and there is evidence
that similar trends are occurring in developing nations, such as China and India
(Cecchini et al., 2010).
Body fat, or adipose tissue, is the main repository for excess energy. The
primary function of adipose tissue is to store the body’s excess energy in the form of
triglycerides. Adipose tissue is primarily made up of fat cells, or adipocytes, but it also
contains other cells types such as macrophages and fibroblasts. Adipose tissue also
contains preadipocytes that can undergo adipogenesis, or differentiate into mature
adipocytes. Adipogenesis is regulated by the transcription factors peroxisome
proliferator activate receptor gamma (PPARγ) and CCAAT-enhancing-binding proteins
(C/EBPs), which, once activated, increase transcription of genes that change cell
morphology and signal the adipocyte to begin storing lipids (Rosen et al., 2000).There
are many different depots of adipose tissue throughout the body, and they each have
different metabolic profiles. One of the most well known depots is the visceral fat that
accumulates around the abdomen. Excessive abdominal fat is the depot most
commonly associated with obesity and its comorbidities. Obesity can proceed through
a combination of adipocyte hypertrophy, hyperplasia, or combination of both (de
Ferranti and Mozaffarian, 2008). As energy intake far outweighs energy expenditure,
adipocytes expand, increasing intracellular lipids. As the adipocytes continue to
2

expand, they signal preadipocytes to proliferate and undergo adipogenesis, thus
increasing the number of mature adipocytes (Avram et al., 2007)
While the primary role of adipose tissue is the storage of excess energy, it is now
known that adipose tissue acts as an endocrine organ (Siiteri, 1987, Zhang et al., 1994).
Along with producing and secreting traditional hormones such as estrogen, adipose
tissue produces and secretes a number of adipose-derive hormones. These hormones
include the appetite regulator, Leptin, and glucose regulator, Adiponectin, as well as the
inflammatory cytokines, tumor necrosis factor, alpha (TNFα) and interleukin-6 (IL-6). A
chronic state of inflammation is associated with excess body fat, which may be a
contributing factor to the diseases associated with obesity such as insulin resistance
and cardiovascular disease (Shoelson et al., 2007). Furthermore, the inflammatory
cytokines released from adipose tissue may promote adipocyte proliferation and
expansion, creating a vicious cycle where adipose tissue expansion promotes
inflammation, which, in turn, promotes adipose expansion (Avram et al., 2007).
Environmental Obesogens
The main driving force promoting obesity is disruption of the body’s energy
homeostasis, i.e. caloric intake far outweighing energy expenditure. Many believe that
humans evolved to be able to sustain long periods of time with little food, and the
modern Western lifestyle (high calorie diet, sedentary lifestyle) has led to the increased
prevalence of obesity (Hales and Barker, 2001). While this theory certainly makes
sense, many believe it doesn’t fully explain the alarming rate of increase seen in the last
3

thirty years. Human exposure to synthetic chemicals has also increased dramatically
over the past half century, concurrently with the increase in obesity (Baillie-Hamilton,
2002). A number of these chemicals are produced during many manufacturing and
agricultural processes. Some are commonly used in many household items making it
difficult to limit human exposure. The “environmental obesogen” hypothesis proposes
that a number of environmental chemicals can disrupt homeostatic energy balance, lipid
metabolism, and adipogenesis, leading to increasing adiposity (Grun and Blumberg,
2007, Grun and Blumberg, 2009a). The term “obesogen” was first used by Dr. Bruce
Blumberg of the University of California Irvine in 2006, and a Pubmed search of
“obesogen” produces only nine hits, so the idea that synthetic chemicals in the
environment can promote obesity is a fairly novel one.
While the term “environmental obesogen” is a new one, the number of chemicals
with possible obesogenic properties is not low. A number of these chemicals are
environmental pollutants, such as phthalates, organotins, bisphenol A (BPA), and
perfluoroalkyl compounds (PFCs) (Grun and Blumberg, 2009a). Other sources of
possible environmental obesogens include nutritional components, such as
phytoestrogens, and pharmaceutical components, such as diethylstilbestrol (DES) and
thiazolidinediones (TZDs) (Newbold et al., 2007, Heindel and vom Saal, 2009).
Perhaps the most compelling evidence for environmental factors contributing to
obesity is the increase in the number of overweight infants; the prevalence of
overweight infants under 6 months old has increased 73% since 1980 (Kim et al., 2006).
Because there is no official definition of overweight for children younger than 24
4

months, overweight was defined as weight-for-length greater than the 95th percentile.
While there are a number of possible explanations for increased adiposity in newborns
(maternal diet, epigenetics, etc.), in utero exposure to environmental pollutants is one
certainly of great concern. Mothers can control their diets, but many of these chemicals
are ubiquitous in the environment making it difficult to limit human exposure
(Vandenberg et al., 2007). The concept of environmental obesogens is closely linked
with Barker’s hypothesis, or “the fetal basis of adult disease” theory. David Barker
proposed this hypothesis in the 1980’s to explain the correlation between low birth
weight and a number of chronic conditions later in life, including cardiovascular disease
and diabetes (Barker et al., 1989). Barker hypothesized that poor nutritional conditions
in utero lead the fetus to adapt to an environment limited in nutrients. The fetus is
essentially programmed for survival in a limited nutrient environment, but is born into an
environment where nutrients are far from limited. The fetal basis for adult disease
paradigm has been validated for obesity by a number of other in utero and perinatal
conditions, such as maternal smoking, that result in increased adiposity later in life. The
effect that in utero exposure to these chemicals may have on development is widely
unknown, but a number of these chemicals are endocrine disruptors, compounds that
can mimic and disrupt the body's natural hormones, specifically estrogen (Grun and
Blumberg, 2009b).
Endocrine Disruptors
Endocrine disruptors are exogenous chemicals that mimic and disrupt the
function of the body’s natural hormones, and prenatal exposure to these chemicals is
5

believed to adversely affect gene expression and development of a number of systems
(Colborn et al., 1993). Furthermore, exposure to these chemicals at other critical times
in one’s lifespan could have detrimental effects on systems that require hormonal signal
to function properly (i.e. sexual development, reproduction, etc.). Reproductive
problems, early puberty, behavioral problems, and even some cancers are some of the
health problems that have been attributed to endocrine disruptors (Birnbaum and
Fenton, 2003, Safe, 2004). These chemicals not only mimic the hormones of humans,
but they can also have the same adverse effects on wildlife that are exposed, raising
concerns about the impact that endocrine disruptors in the environment may have on a
variety of organisms (Kloas, 2002).
An endogenous hormone binds its specific or group of specific hormone
receptors to mediate its signaling and action. Endocrine disruptors, which generally
share some structural similarity with the endogenous hormone, can also interact with
the hormone receptor leading to disruption of the process. An endocrine disruptor may
not be biologically active leading to attenuation of the signaling, or it may be more
biologically active than the endogenous hormone leading to increased signaling.
Endogenous hormones are also regulated by the body in a number of ways, including
feedback inhibition, none of which would have an effect on exogenous endocrine
disruptors (Zoeller, 2005, Ghisari and Bonefeld-Jorgensen, 2005).
The effect that endocrine disruptors have on the function of sex steroids, such as
estrogen and androgen, is of particular concern. Dysfunction in the secretion or action
of these hormones can lead to male reproductive dysfunction in wildlife and humans,
6

alike (Safe, 2004, Kloas, 2002). While the primary function of adipose tissue is to store
energy in the form of fat, it is now known that adipose tissue also acts as an endocrine
organ, synthesizing and secreting its own set of hormones known as
adipokines(Kershaw and Flier, 2004). Adipocytes also express and secrete sex
hormones, such as estrogen, and their receptors, and these hormones regulate adipose
tissue development (Siiteri, 1987). Therefore, endocrine disrupting chemicals could
potential disrupt adipocyte metabolism and energy homeostasis. Knockout models for
certain components of the sex steroid pathway (aromatase, estrogen receptor, etc.) can
result in dysregulation of adipocyte size and number and affect the sexually dimorphic
deposition of adipose tissue (Heine et al., 2000, Murata et al., 2002). Loss of estrogen
in mice via ovariectatomy results in weight gain and obesity, and menopausal women
tend to gain body fat (Demir et al., 2008). Taken together, these data suggest that sex
hormone dysregulation can have pro-adipogenic effects.
There are also a number of nuclear hormone receptors that act as regulators of a
number of pathways important to adipose tissue, such as lipid metabolism and
adipocyte proliferation and differentiation. Peroxisome proliferator activated receptors
(PPARs) are the most important of these receptors, particularly the gamma isoform
(PPARγ). Activated PPARγ increases the expression of key adipogenic genes that
promote the storage of fatty acids and decreases the expression of lipolysis genes
(Ferre, 2004). PPARs form heterodimers with 9-cis retinoic acid receptor (RXR) that
can function as metabolic sensors for a variety of lipophilic hormones. The formation of
preadipocytes from mesenchymal stem cells, as well as differentiation of preadipocytes,
7

is dependent on the activation of RXR-PPARγ (Rosen et al., 1999). The anti-diabetic
drugs rosiglitazone and pioglitazone are PPARγ agonists that improve insulin sensitivity
but result in increased weight gain (Larsen et al., 2003). The fact that a pharmaceutical
agent can act as an obesogen through the activation of PPARγ would suggest the
possible existence of other chemicals with similar effects. Recent findings have shown
that some organic pollutants that are endocrine disrupting chemicals can also activate
both the RXRs and PPARγ (Grun et al., 2006).
Bisphenol A
Bisphenol A (BPA) is an organic compound containing two equivalent phenol
groups that was first synthesized in 1891 (Figure 1-1). In the 1930’s, it was discovered
that BPA has estrogenic properties, however its use as a synthetic estrogen was
abandoned in favor of diethylstilbestrol (DES), which was determined to have more
potent effects. DES was prescribed to women to help with difficult pregnancies, but it
was discovered after it had been given to millions of women, over 30 years later, that
DES was a carcinogen and could lead to reproductive defects in girls born to mothers
taking DES. If DES could have such an adverse effect, it stands to reason that a
chemical with similar chemical structure and properties such as BPA could have similar
toxic effects.
In the 1940’s, BPA began to be used in the production of plastics. BPA is used
as a hardening agent in consumer plastics and is found in a number of different types,
including widely used polycarbonate plastic. It is also used in dental sealants and
8

Figure 1-1. Chemical structures of Bisphenol A (BPA), diethylstilbestrol (DES), and
estradiol (E2).
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fillings, CDs/DVDs, and household electronics. The epoxy resins that are used in
canned food and beverage linings contain BPA, and it has commonly been used in the
plastics that make baby bottles. The widespread use of BPA has led it to be one of the
most produced chemicals in the world, at 2 million tons a year (Lang et al., 2008). The
increased production and prevalent use has made BPA a ubiquitous chemical in
theenvironment. The population is directly and chronically exposed to BPA through
consumption due to its use in food and beverage packaging and storage containers,
with exposure increased due to the fact that BPA leaches from plastics when exposed
to heat or acidic environments (Le et al., 2008, Vandenberg et al., 2007).
Many of the effects that BPA has on health were first discovered by accident. In
1993, it was discovered that BPA leached from autoclaved polycarbonate flasks,
leading to increased proliferation of breast cancer cells (Krishnan et al., 1993).
Accidental exposure to BPA due to damaged polycarbonate cages led to disruption of
meiosis in the oocyte of control female mice (Hunt et al., 2003). A study from the vom
Saal lab tested the effects of BPA on blood serum and found that BPA had a higher
binding affinity in serum than estradiol, indicating greater estrogenic bioactivity (Nagel et
al., 1997). Furthermore, exposing pregnant mice to small amounts of BPA (2µg/kg/day)
resulted in significantly larger prostates in male offspring compared to controls. This
dose was 25,000 times lower than the toxic threshold set by the EPA
(http://www.epa.gov/IRIS/subst/0356.htm).
The concern over BPA has grown over the last few years; however, there is still
much debate over the potential effects of BPA exposure. One issue is the lack of
10

consistency in findings, and a number of studies contradict one another. Perhaps some
of the dispute can be traced to the chemical companies that have an interest in
protecting their multi-billion dollar industry. Over 90% of independently funded studies
have found that BPA exposure at biologically relevant doses result in adverse health
effects. However, every industry-funded study has found that BPA has no effect on
health (vom Saal and Myers, 2008).
While chemical companies are trying to protect their own interest, there is
legitimate debate and differences of opinion over data interpretation and the potential
toxicity of BPA. For decades, a traditional toxicological approach was taken to study the
effects of BPA. Extremely high doses of BPA were found to have adverse effects such
as organ failure and cancer, but doses below a certain threshold were safe. There is
now evidence that low doses, well below the threshold, have a completely different set
of effects, which can effect development and metabolism. Proponents of BPA still
dispute these findings, saying that the doses used in many of these studies (micromolar
range) are still higher than environmentally relevant doses (low nanomolar range) (BenJonathan et al., 2009). Another issue is the non-monotonic dose response of BPA.
Most studies lack a linear dose-dependent curve of BPA effects, making it difficult to
extrapolate the action of BPA. While the debate remains open, it is clear that BPA can
act as an endocrine disruptor that can possibly disrupt a number of metabolic
processes.

11

Bisphenol A and Obesity
BPA’s endocrine disrupting properties, and its abundance in the environment has
led it to be categorized as a potential environmental obesogen. The potential for BPA to
increase adiposity was also first discovered by accident in 2001. The Rubin lab was
studying the reproductive effects that BPA exposure had on pregnant rats. There had
been some studies on the effect of BPA exposure in adult rodents but very few had
examined the effects of perinatal exposure, which could produce more detrimental and
irreversible effects. They found that the rats treated with a high dose (1.2 mg/kg body
weight (bw)/day) or low dose (0.1 mg/kg bw/day) of BPA via drinking water produced
heavier offspring compared to controls, and this phenotype persisted through adulthood
(Rubin et al., 2001). Interestingly, the offspring from the lower dose were slightly
heavier than the offspring of the high dose, indicating that the lower doses may be more
detrimental in regards to adiposity than higher doses. They also found that female
offspring exposed to the high dose had altered estrous cycles and decreased levels of
plasma luteinizing hormone.
There have been a limited number of studies that further explored these effects
of BPA, and a number of them have used extremely high doses. Some in vitro studies
have shown that BPA can promote adipogenesis, increase expression of adipogenic
genes, and promote inflammation. Hugo and colleagues studied the effects that low
doses of BPA and E2 have on secretion of adiponectin from adipose explants and
mature adipocytes. They found that low nanomolar doses (0.1nM and 1nM) inhibited

12

Table 1-1. Summary of studies: BPA and its role as an environmental obesogen
Model
In vitro studies
murine macrophages
3T3‐L1 preadipocytes
Human adipose
explants/isolated adipocytes
3T3‐L1 preadipocytes
human granulosa cells
In vivo studies
Pregnant CF‐1 mice

Pregnant Sprague‐Dawley rats
Pregnant Sprague‐Dawley rats

Epidemiological studies
NHANES 2003/04 survey
(1453 adults)
NHANES 2005/06 survey
(1493 adults)

BPA Dose

Physiological Effect

Reference

10nM, 100nM,
1µM
80µM

↑ production of IL‐6, TNFα, MCP‐1

Yamashita et al.
2005
Phrakonkham et
al. 2008
Hugo et al. 2008

0.1nM, 1nM
1µmol/L
40, 60, 80,
100µM
2.4µg/kg bw/day
(gestation day
11‐19)
1mg/L, 10mg/L
1mg/L (gestation
day 6‐lactation)

NA
NA

↑ expression of adipogenic transcription
factors
↓ secretion of adiponectin
↑ activation of glucocorticoid receptor,
lipid accumulation
↓ E2 secretion, ↑ PPARγ activation

Sargis et al. 2009

↑ female offspring body weight, early
onset of puberty

Howdeshell et al.
1999

↑ offspring body weight
↑ offspring body weight, parametrial WAT
3‐fold (females), expression of lipogenic
genes (females), adipocyte size (females)

Rubin et al. 2001
Somm et al. 2009

↑ urinary BPA associated with CVD,
diabetes, and higher BMI
↑ urinary BPA associated with coronary
heart disease

Lang et al. 2008

Kwintkiewicz et
al. 2010

Melzer et al. 2010

13

adiponectin secretion from adipose tissue and mature adipocytes, alike (Hugo et al.,
2008). They also found that BPA increased the secretion of the pro-inflammatory
cytokines, tumor necrosis factor α (TNFα) and interleukin-6 (IL-6). Sargis and
colleagues tested the ability of a number of endocrine disrupting chemicals (EDCs) to
stimulate the glucocorticoid receptor (GR) due to its central role adipocyte differentiation
(Sargis et al., 2009). They treated 3T3-L1 preadipocytes with a variety of EDCs and
assessed the ability of each to activate GR using a luciferase reporter construct. They
found that BPA was one of four chemicals that stimulated activationof GR at a
concentration of 1 µmol/L. BPA also increased lipid accumulation in differentiating
adipocytes and increased expression of adipogenic proteins.
Howdeshell and colleagues fed pregnant mice BPA at a dose of 2.4µg/kg bw
between days 11 and 17 of gestation. The offspring had similar birth weights.
However, after weaning, female mice treated with BPA were significantly heavier than
female controls (~10.5g compared to 9.25g). The results were very similar in the male
counterparts (Howdeshell et al., 1999). They also found that the female mice exposed
to BPA began ovulation earlier. To our knowledge, there has been only one study that
has addressed BPA’s effect on fat tissue. The Somm laboratory sought to determine
the effect that perinatal exposure to BPA has on early adipose storage. Pregnant rats
were exposed to BPA through drinking water at a dose of 1mg/L at day 6 of gestation
through the end of lactation. The offspring were weaned and sacrificed at day 21 to
study the perigonadal adipose tissue. They found that the birth weight for both males
and females exposed to BPA were increased, however the body weight was only
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increased in the females at the time of sacrifice. They also found that gestational
exposure to BPA increased parametrial white adipose tissue (WAT) in female rats 3fold. The increased pWAT was attributed to adipocyte hypertrophy; females exposed to
BPA had significantly larger adipocytes (Somm et al., 2009). The exposed females also
had increased expression of lipogenic genes, such as Pparg and fatty acid synthase
(Fasn). These studies indicate that BPA exposure, particularly early in life, may alter
adipose energy homeostasis in a way that is promoting fat storage and obesity,
however the effect of postnatal and early childhood exposure remains unknown.
BPA is a lipophilic compound, therefore, it can accumulate in fat. Obesity is
associated with chronic low-level inflammation that can contribute to further
complications, such as cardiovascular disease (Grundy, 2004, Xu et al., 2003). BPA
has been shown to upregulate important inflammatory cytokines and adipokines in
adipose tissue explants, and a few in vitro studies have shown that it increases
expression of pro-inflammatory cytokines, such as TNFα and IL-6 in macrophages
(Yamashita et al., 2005, Yan et al., 2008, Hugo et al., 2008). Mice exposed to low
levels of BPA in utero exhibited increased production of T-cell activating cytokines and
diminished numbers of regulatory T-cells as adults, favoring inflammation (Yan et al.,
2008). In humans, there have been significant correlations shown between urinary BPA
levels and markers for inflammation (Melzer et al., 2010), and in post- but not premenopausal women, significant correlations have been shown between urinary BPA
concentrations and markers of oxidative stress and inflammation (including C-reactive
protein), suggesting interactions with estrogen-related signaling (Yang et al., 2009).
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Both adipocytes and the stromal vascular fraction of cells in adipose tissue secrete proinflammatory cytokines. Studies now indicate that the inflammatory process of obesity
begins before there are large changes in adipose tissue mass due to the infiltration of
macrophages and CD8+ T-cells. These cells disrupt adipocyte metabolism and insulin
sensitivity by secreting cytokines and promoting local inflammation within the adipose
tissue (Greenberg and Obin, 2006, Cinti et al., 2005). If BPA increases adipose mass
through adipocyte hypertrophy or hyperplasia, there would be an expected parallel
increase in inflammatory adipokines. This indirect effect along with the direct effect that
BPA may have on expression of TNF-α and IL-6 could have great consequences,
specifically the manifestation of the metabolic syndrome.
Along with promoting inflammation, there is concern that developmental
exposure to BPA may increase the number of adipocyte precursors and promote
adipocyte differentiation. 3T3-L1 fibroblasts treated with BPA increased expression of
important adipogenic genes, however, the doses used were well outside the biologically
relevant range (Phrakonkham et al., 2008, Vandenberg et al., 2009). If BPA increases
preadipocyte proliferation, adipogenesis, and inflammation at doses similar to human
exposure (low nanomolar range), it could be an important contributing factor to the
metabolic syndrome and the current obesity epidemic (Figure 1-2).
There have been a number of epidemiological studies to determine the level of
exposure to BPA in humans and the possible adverse health effects of exposure.
Perhaps the most widely known is the data acquired from the National Health and
Nutrition Examine Survey (NHANES). The NHANES 2003/2004 survey provided the
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Figure 1-2. Model depicting various factors contributing to obesity and
the metabolic syndrome. BPA decreases secretion of Adiponectin which
results in decreases in insulin sensitivity. BPA also increases secretion of
inflammatory cytokines from adipocytes which promotes insulin resistance as
well as atherosclerosis and hypertension, all of which are part the metabolic
syndrome (Ben-Jonathan et al., 2009).
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first large scale view of BPA levels in the US population. Approximately 1500 adult
participants, ages 18 to 74, with measured urinary BPA were assayed for chronic
disease diagnosis as well as markers of liver function, glucose homeostasis,
inflammation, and lipid changes. BPA was detected in the urine of over 92% of
participants. This study found that higher urinary BPA levels were associated with
increased incidence of coronary heart disease, even after regression models are
adjusted for sex, age, smoking, BMI and other known variables that affect
cardiovascular disease (Lang et al., 2008). Higher BPA concentrations were also
associated with diabetes, and individuals with BMI’s over 35 had nearly twice the level
of BPA compared to individuals within the normal range (6.93 ng/mL compared to
3.91ng/mL). This study also suggested correlation between C-reactive protein levels
and urinary BPA , although the relationship did not reach statistical significance when
the model was fully adjusted for all potential covariates.
In a more recent study, Melzer and colleagues (Melzer et al., 2010) conducted a
similar cross-sectional analysis with data from the NHANES 2005/06 study as well as
data pooled across both studies. Despite average BPA levels being 30% lower in the
2005/06 group compared to the 2003/04 group, they also found that higher urinary BPA
levels were associated with coronary heart disease in the 2005/06 cohort, as well as the
pooled data. However, association with diabetes was not significant in the 2005/06
data, but remained significant in the pooled data. The decrease in average BPA levels
is most likely due to increased consumer awareness and the decreased use of certain
plastics. One group absent from the previously mentioned studies is children. Another
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study to assess BPA exposure in the US general population included children of 6 years
of age or greater (Calafat et al., 2008). They found that children ages 6-11 had the
highest levels of urinary BPA of any age group, indicating a disproportionate level of
accumulation or exposure in children. This is especially troubling considering children
may be the group most susceptible to BPA’s potential toxic effects.
Metabolic actions of BPA
While it is unknown how BPA mediates its action on adipose tissue and other
systems, there are a few of potential interactions that could explain BPA’s effect (BenJonathan et al., 2009). The most well known interaction occurs between BPA and the
classical estrogen receptors ERα and ERβ. BPA has been shown to interact with these
receptors (Gould et al., 1998, Kuiper et al., 1998), and it’s possible that BPA disrupts
the endogenous estrogen signaling. However BPA binds these receptors much weaker
than estradiol and should not be able to compete with endogenous estrogen at the low
levels that humans are exposed, yet it does (Gould et al., 1998). There are a number of
speculations to explain the disparity. It is thought that BPA may bind to the estrogen
receptors differently than endogenous estradiol as a result of some interaction between
BPA and serum proteins or some co-ligands. These interactions allow BPA to bind the
ERs near the same strength of estradiol and compete in the nanomolar range
(Welshons et al., 2006, Safe et al., 2002). BPA may also elicit a rapid response by
binding non-classical membrane estrogen receptors (ncmERs) (Alonso-Magdalena et
al., 2005) or estrogen-related receptors (ERRs) (Ben-Jonathan et al., 2009, Takayanagi
et al., 2006). In fact, Nadal et al. found that, in pancreatic islets, BPA may mimic the
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actions of E2 on blood glucose homeostasis through two different pathways: a rapid
pathway via ncmER and a prolonged pathway via ER. Overstimulation of these
receptors by BPA on the β-cells increased insulin biosynthesis and secretion leading to
insulin resistance.
There have been few studies looking at the effects of BPA on adipose tissue in
vivo; however many of these have conflicting data, most likely due to the wide range of
doses used. Some studies have found that BPA exposure increases adipose mass in
rats (Somm et al., 2009), and others find that certain doses have no effect or actually
decrease body weight (Nunez et al., 2001, Seidlova-Wuttke et al., 2005). This is a major
issue with attributing BPA to a number of adverse effects. As stated previously, Hugo et
al. found that BPA at low nanomolar concentrations inhibited the release of adiponectin
from isolated human adipocytes and stimulated the release of IL-6 and TNFα, a direct
effect of BPA that would be predicted to diminish insulin sensitivity (Hugo et al., 2008).
There is also evidence that BPA may activate the key adipogenic regulator PPARγ.
BPA treatment significantly up-regulated PPARγ in a dose dependent manner in human
granulose cells, resulting in reduced insulin-like growth factor 1 (IGF-1) and aromatase
expression and E2 secretion (Kwintkiewicz et al., 2010).
It is clear that BPA has endocrine disrupting properties and can have adverse
effects on health, especially at extremely high doses. The effects that BPA has at low
doses are not quite as clear. Along with studying the effects that nanomolar doses of
BPA has on adipocyte endocrine function, gene expression, and overall adiposity, we
are also interested in how BPA affects adipocyte metabolism. Our goal is to determine
20

if biologically relevant levels of Bisphenol A (BPA) effect the development, endocrine
function, and metabolism of adipose tissue in a way that promotes obesity.
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CHAPTER II
GENERAL EXPERIMENTAL DESIGN
Our goal is to determine if biologically relevant levels of Bisphenol A (BPA) effect
the development, endocrine function, and metabolism of adipose tissue in a way that
promotes obesity. The ultimate purpose is to identify the potential metabolic pathways
and genes that mediate response to BPA and ultimately understand the effects of BPA
on adiposity. The research employed both in vitro and in vivo methods to meet these
goals.
We began by assessing the effects of BPA using in vitro systems. Adipose
tissue ex-plants were exposed to varying doses of BPA and analyzed for gene
expression and changes in metabolism. We also used mesenchymal stem cells
(MSCs) to assess the effects that BPA has on proliferation and adipogenesis (Part 1).
Secondly, we used two strains of mice (C57BL/6J and DBA/2J) to look at the
effects that biologically relevant levels of BPA has on overall adiposity and adipose
tissue gene expression, endocrine function, and metabolism (Part 2). BPA was
delivered orally, via drinking water, which is the most common route of exposure in
humans. Mice were exposed to BPA from 4 weeks of age to 12 weeks of age.
Intraperitoneal glucose tolerance tests (GTTs) were conducted at 8 weeks of age.
Adipose tissue was collected and analyzed for changes in gene expression (Illumina®),
metabolism (mass spectrometry), and protein levels (Luminex®). We also collected
serum to look at fasting insulin levels.
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Figure 2-1. Experimental design: in vitro experiments. Adipose tissue explants
from 16 BXD mice were exposed to various concentrations of BPA and estradiol for 24
hrs. Tissue was then snap frozen and pulverized for metabolic and gene expression
analyses. Mouse mesenchymal stem cells were treated with various concentrations of
BPA and estradiol for 24 or 48 hours and proliferation rate was determined using the
CellTiter 96 AQueous One Proliferation Assay (Promega.com).
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Figure 2-1. Experimental design: in vivo experiment. Mice were exposed to various
doses of BPA and sacrificed after 8 weeks of treatment. Adipose tissue was harvested
an snap frozen or placed in RNAlater. Tissue was used to analyze gene expression,
metabolomics, and protein levels.
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CHAPTER III
EFFECTS OF BISPHENOL A ON ADIPOCYTE GENE EXPRESSION,
METABOLISM, AND PROLIFERATION
Introduction
Bisphenol A (BPA) is a chemical found in many items that humans use daily,
including polycarbonate plastics. BPA is structurally similar to the potent synthetic
estrogen, diethylstilbestrol (DES), and it is clear that BPA has endocrine disrupting
properties as well (Alonso-Magdalena et al., 2005, Krishnan et al., 1993). Adipose
tissue has a critical role as an endocrine organ, along with its role of energy storage. It
not only responds to traditional hormones, but it also produces and secretes its own set
of peptides, adipokines, which play an important role in regulating physiology and
inflammation (Kershaw and Flier, 2004). Adipose tissue also produces and secretes
sex hormones (Siiteri, 1987). Therefore, a known endocrine disruptor such as BPA
could have an adverse effect on the endocrine function and metabolism of adipocytes.
We hypothesize that low doses of BPA, similar to levels exposed to humans, can
disrupt normal gene expression and endocrine function in a way that would promote
adipocyte expansion and inflammation.
Adipose tissue is primarily made up of adipocytes, but it also consists of a
variety of other cell types including fibroblasts and macrophages (Balistreri et al., 2010,
Gaetani, 2008). BPA has been shown to increase the secretion of the pro-inflammatory
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cytokine, TNFα, from adipose tissue (Ben-Jonathan et al., 2009). If BPA increases
adipose tissue mass, there were would a parallel increase in inflammation. However, if
BPA directly increases expression and secretion of pro-inflammatory adipokines, this
could increase the number of infiltrating macrophages which would further exacerbate
the inflammation and increase the risk of developing cardiovascular disease or type II
diabetes (Hugo et al., 2008, Fantuzzi, 2005). We measured the expression of two
important inflammatory adipokines, TNFα and IL-6, in adipose tissue explants exposed
to BPA. There is also a strong correlation between TNFα production, adiposity, and
insulin resistance (Ryden and Arner, 2007). . If BPA directly increases production of
inflammatory adipokines, this would support the idea that BPA and other endocrine
disruptors can regulate inflammatory adipokines independent of adipocyte hypertrophy
(Newbold et al., 2007),
We also measured the expression of the adipogenic regulator, PPARGγ, and the
lipogenic gene, FASN. Adipogenesis is the process of preadipocytes differentiating to
mature adipocytes (Rosen et al., 1999). This process is regulated by the transcription
factor PPARγ, and there is evidence that BPA may activate this adipogenic regulator
(Chen et al., 2009a, Grun et al., 2006). Fatty acid synthase (FASN) is a large multienzyme complex responsible for the synthesis of long-chain fatty acids (Sul et al.,
2000). If BPA was to increase the expression of one or both of these genes, it would
indicate that BPA may promote adipose expansion through increased adipogenesis and
lipogenesis.
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Adiposity can increase through adipocyte expansion (hypertrophy), proliferation
(hyperplasia), or a combination of both. The number of adipocytes remains mostly
constant throughout adulthood for both lean and obese individuals, which indicates that
the number of adipocytes is determined at a young age (Spalding et al., 2008).
Developmental exposure during gestation to BPA has been shown to increase birth
weight which persist into adulthood and is associated with increased fat mass (Somm et
al., 2009). We believe that a possible explanation for this is that developmental
exposure to BPA increases the proliferation of adipocyte precursors which leads to an
increase in adipose tissue capacity later in life. Mesenchymal stem cells (MSCs) are a
major source for adipocyte progenitors, as well as bone and cartilage cells and are,
therefore, a good model to study the effects that BPA has on adipocyte precursor
proliferation. To determine if BPA exposure could increase the number of adipocyte
precursors, we treated mouse mesenchymal stem cells with BPA assayed the
proliferation rate compared to controls. An increase in proliferation of MSCs with BPA
treatment would indicate that developmental exposure could possibly program an
individual for increased fat mass.
Our overall goal for this study was to determine if low levels of BPA creates an
adipose tissue phenotype that is sensitized to expansion through increased proliferation
of adipocyte precursors, altered energy metabolism, and changes in gene expression
that favor obesity. We chose to use mouse adipose tissue explants as a model rather
than 3T3-L1 fibroblasts, which is a typical cell model used to study adipocytes, because
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the sensitivity of estrogen receptors to estrogens has been questioned (Rubin and Soto,
2009). This model also provided a better representation of adipose tissue in vivo.

Methods
Materials
Stock solutions of BPA (Invitrogen, Inc.) were prepared in the Campagna lab
(Chemistry Dept., UTK) using distilled ethanol. The ethanol was distilled to prevent
contamination with additional estrogenic compounds leaching from the plastic bottles.
The mouse mesenchymal stem cells were obtained from Invitrogen Life Technologies,
Inc. (Gaithersburg, MD) and were isolated from the bone marrow of C57BL/6 mouse at
≤ 8 weeks after gestation. DMEM/F-12 media, Phenol-free DMEM and fetal bovine
serum (FBS) were also obtained from Invitrogen Life Technologies, Inc. All quantitative
PCR (QPCR) primers were predesigned QuantiTect, and the primers and master mix
were obtained from Qiagen, Inc. (Valencia, CA).
Adipose tissue explants and treatment
Perigonadal white adipose tissue (pWAT) was harvested from 16 surplus BXD
recombinant inbred mice and pooled together in phenol-free DMEM (Invitrogen)
supplemented with 10% charcoal-stripped FBS to minimize endogenous estrogen
exposure. The adipose tissue was cultured in glass plates to prevent outside sources of
BPA. After 24 hours, the adipose tissue was split into six treatment groups plus a
control group (4 plates/treatment; n=4): control, 1nM, 10nM, 100nM, and 1µM BPA,
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10nM E2, and 10nM E2 + 10nM BPA. The tissue was pooled together and split into
treatment groups to avoid confounding effects. After an additional 24 hours of
treatment, the tissue was snap frozen and pulverized using a mortar and pestle for
metabolic and gene expression analysis.
Metabolomics
Approximately 15 mg of each adipose tissue sample was weighed into 1.5 mL
centrifuge tubes. Cold methanol (500 µL at -78oC) and the internal standards, tris (5 µL
of 4.7mM in H2O) and benzoic acid (5 µL of 1.7 mM in H2O), were added to each tube,
and then mixed by vortexing for 2 min. The metabolites were extracted for 30 min at 4oC
on ice, which precipitates the enzymes, followed by centrifugation (5 min, 13.2 rpm,
16.1 rcf, 4oC). Supernatants were split into two autosampler vials each. One vial was
placed directly in the autosampler for analysis, and the other was frozen at -80oC for
analysis in the opposite mode the following day. High performance liquid
chromatography (HPLC) was performed utilizing a quaternary pump to generate a
gradient for the elution of compounds from the stationary phase. For all samples, 10 µL
was injected onto the column via an autosampler cooled to 4 °C. Eluent was directly
introduced into the electrospray ionization (ESI) chamber of the triple quadrupole mass
spectrometer. Samples were analyzed using selected reaction monitoring (SRM), and
the scan time for each SRM was 0.05 s with a scan width of 1 m/z. Raw files for each
sample were first processed using mzRock, and once the data set was narrowed,
Xcalibur Quan Browser was used to visualize and manually integrate metabolite peaks
over a set time window.
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RNA isolation and quantitative PCR
Total RNA was extracted from adipose tissue using the RNeasy™ Lipid Tissue
Mini Kit (Qiagen, Inc.). The RNA quality and concentration were assessed using the
Nanodrop™ 2000 spectrophotometer (Thermo Scientific, Inc.). We reverse transcribed
500ng total RNA using the iScript™ cDNA synthesis kit (Bio-Rad) which uses a
modified MMLV-derived reverse transcriptase and a combination of oligo(dT) and
random hexamer primers. The relative expression of transcripts coding for mouse Tnfa
(tumor necrosis factor alpha), Il6 (interleukin-6), Fasn (fatty acid synthase), and Pparg
(peroxisome proliferator-activated receptor gamma) were measured by quantitative realtime PCR (QPCR) using a CFX96™ Real-Time PCR Detection System (Bio-Rad) and
were normalized using the housekeeping gene hypoxanthine guanine phosphoribosyl
transferease (Hprt). All samples were analyzed in triplicate. We quantified the
expression using the QuantiTect SYBR Green PCR kit and QuantiTect Primer Assays
(Qiagen, Inc.), and relative gene expression was determined using the ∆∆Ct method
and the Relative Expression Software Tool (REST) (Pfaffl et al., 2002).
Proliferation Assay
Mouse mesenchymal stem cells (MSCs) were plated in a 96-well culture plate at
a density of ~5,000 cells per well and grown in DMEM/F-12 media. The cells were
allowed to attach and grow for 24 hours, then the media was replaced containing the
one of the following: vehicle control (EtOH), 1nM BPA, 10nM BPA, 1µM BPA, 10nM E2,
or 10nM E2 + 10nM BPA. The cells were treated for either 24 or 48 hrs. Cell
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proliferation was measured using the CellTiter 96 AQueous One Solution Cell
Proliferation Kit (Promega). Briefly, the AQueous One Solution contains an MTS
tetrazolium compound which is reduced by living cells to a soluble, colored formazan
product. This product’s absorbance can be measured at 490nm and is directly
proportional to the number of living cells in culture.
Statistical analysis
The QPCR data were analyzed using REST which uses a mathematical model
based on the correction for exact PCR efficiencies and the mean threshold value (Ct)
deviation between treatment groups and the control group. The expression ratios were
then tested for significance using a Pair Wise Fixed Reallocation Randomisation Test©.
Differences in proliferation were analyzed using one-way analysis of the variance
(ANOVA), and once significance was determined, post hoc tests (t-tests and LSD) were
performed.

Results
Adipose tissue explants were treated with BPA or estradiol for 24 hours.
Following treatment, we analyzed the gene expression of some inflammatory markers
as well as lipogenic/adipogenic genes. Our data suggest that exposure to BPA
increases expression of inflammatory cytokines (Figure 3-1). There were statistically
significant (p<0.05) increases in Tnfa expression at 10nM and 1µM concentrations and
significant increases in Il-6 at the 1µM dose. Tnfa was increased 2.2-fold and 1.98-fold
in the 10nM and 1µM treatment, respectively. Il-6 expression was increased 2.76-fold
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Figure 3-1. QPCR results for selected genes in mouse adipose tissue explants.
Data were analyzed using REST and results are expressed as means ± SEM. (*)
indicates significant difference from control (p<0.05).
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in the 10nM treatment. There were also significant increases in the expression of Fasn
at 10nM and 1µM concentrations (1.79-fold and 2.98-fold, respectively), which would
suggest a possible increase in lipogenesis activity. Pparg expression was unchanged,
indicating that BPA is not enhancing adipogenesis. However, BPA may possibly
increase the activity of Pparg without affecting its expression. Estradiol did not appear
to alter the expression of any of the genes. Our sample size was small (n=4) and could
explain a lack of significant results at additional treatments, however these results are
consistent with experiments previously conducted in our lab as well as by others (Yan et
al., 2008).
Technical advances in recent years have advanced the ability to use global
metabolomics to query changes in profiles of small molecule metabolites in serum and
tissues. It has been proposed that BPA alters adipose tissue energy metabolism which
leads to an increase in adipose mass (Chen et al., 2009b). After the adipose tissue
explants were treated with BPA for 24 hours, metabolites were extracted from the tissue
and analyzed using mass spectrometry. The metabolite ratios were calculated after
correcting ion counts for mass and signal difference. The data shown represent ratios
of select metabolites in treated vs. control adipose tissue. Due to the small sample size,
there were no statistically significant differences between any treatments and control,
however there was a trend for increased glycolytic and TCA cycle intermediates with
BPA treatment, which are important pathways in energy metabolism (Figure 3-2).
These data indicate that BPA may alter energy metabolism in adipose tissue.
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Figure 3-2. Metabolic profiling of BPA-treated adipose tissue. LC-MS/MS was
used to measure metabolite levels in white adipose tissue treated with various
concentrations of BPA or estradiol.
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Mouse mesenchymal stem cells (MSCs) were treated with BPA or estradiol for 24 or 48
hours to analyze the effect on proliferation. We believe that in utero and perinatal
exposure to BPA can possibly “program” a person to be obese by increasing
proliferation of adipocyte precursors which would increase the adipose capacity later in
life. The CellTiter 96 AQueous One Proliferation Assay was used which measures the
formation of formazan from a tetrazolium compound and is correlated with the number
of viable cells in culture. We found that all three concentrations of BPA used modestly
but significantly increased proliferation (1.18-1.21-fold increase, p<0.05) of MSCs at
both 24 and 48 hours (Figure 3-3). The estradiol treatment did not increase proliferation
after 24 hours, but it did increase proliferation similar to BPA after 48 hours. The
combination of BPA and estradiol did not have a significant effect on proliferation.

Discussion
To start to study the effects that BPA has on adipose tissue development and
function, we began by using in vitro and ex vivo models. We used a wide range of
concentrations of BPA ( low nM – low µM) because the effects of BPA are often nonmonotonic (Ben-Jonathan et al., 2009). Just because there is an effect at a specific
dose doesn’t mean that effect is going to be exacerbated at higher doses, and vice
versa. Traditional toxicological studies generally take a “dose makes the poison”
approach, but BPA may actually have a greater effect at lower levels, in some cases.
Since BPA is known to have estrogenic properties, we also used a 10nM concentration
of estradiol and a combination of 10nM BPA and 10nM estradiol to compare the effects
of a natural hormone and a chemical that mimics the natural hormone. Adipose tissue
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Figure 3-3. Effects of BPA and E2 on proliferation of mouse mesenchymal stem
cells. Mouse MSCs were treated with various concentrations of BPA or E2 for 24 or 48
hours. Proliferation was assayed using the CellTiter 96 AQueous One Proliferation
Assay (Promega). (n=22/treatment, * p<0.05).
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explants were chosen to be used because they are a better representation of adipose
tissue in vivo, and there is evidence that the adipocyte cell line, 3T3-L1, which we
normally use as a model of adipose tissue may underexpress ERs, which are candidate
mediators of BPA action (Rubin and Soto, 2009).
The gene expression data shown in Figure 3-1 indicate that the expression levels
of the pro-inflammatory cytokines Tnfa and Il-6 are increased in some treatments of
BPA. The 10nM concentration of BPA significantly increased the expression of Tnfa
and Il6 2.19-fold and 2.67-fold, respectively. The 1µM concentration of BPA also
significantly increased Tnfa expression by 1.95-fold. While some of the other
concentrations of BPA increased the expression of these cytokines, they were not
significantly different from the control treatment, which may be a result of our small
sample size (n=4). We also measured the expression of Fasn and Pparg as markers of
lipogenesis and adipogenesis, respectively. While there was no change in expression
of Pparg, Fasn expression increased 1.8-fold and 3-fold in 10nM BPA and 1µM BPA,
respectively. This increase in fatty acid synthase expression would indicate the
possibility that BPA promotes enhanced de novo lipogenesis.
There are some additional interesting things to take from these data. The gene
expression data across the doses of BPA creates an inverted ‘U’ shape curve,
specifically for the cytokines. The 10nM dose of BPA seems to increase the expression
of Tnfa and Il6, yet this effect isn’t enhanced in the 100nM or 1µM dose, but, rather
diminished. This result is consistent with the non-monotonic effects often seen in BPA
studies (Ben-Jonathan et al., 2009). The estradiol treatment did not seem to affect the
37

gene expression of any of the genes tested, however the combination treatment of
10nM BPA and 10nM estradiol seemed to attenuate the effects seen in the 10nM BPA
treatment alone. This could reflect a competition between the two molecules for the
same receptor(s), possibly ERs.
Along with our collaborator, Dr. Shawn Campagna, we performed global
metabolic profiling using small molecule metabolic mass spectrometry to query changes
in metabolite pools from adipose tissue treated with BPA. It is believed that BPA
mediates its action through ERs, which are now known to play a key role in energy
metabolism (Chen et al., 2009a, Gao et al., 2007). Disruption of adipose energy
balance has been proposed as a mechanism through which BPA increases adipose
mass (Chen et al., 2009b). The data presented in Figure 3-2 represent ratios of
glycolytic and TCA cycle metabolites in treated vs. control adipose tissue; ratios were
calculated after correcting ion counts for mass and signal differences. These data
indicate a trend for increasing doses of BPA to alter adipose energy metabolism,
particularly intermediates of glycolysis. Due to the method used, traditional statistical
methods were not used to analyze the metabolomics data, rather we looked at the foldchange: a fold-change of 1.5 or greater was considered interesting. Once again there is
no monotonic response to increasing BPA concentration, but changes to metabolites
spread throughout doses in both glycolytic and TCA cycle intermediates. The 1µM
concentration of BPA was the only dose that had a 1.5 fold or greater increase in all the
metabolites shown.
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Glucose is broken down via glycolysis into 2 molecules of pyruvate which then
enter the mitochondria, are converted to acetyl-CoA, and enter the tricarboxylic acid
(TCA) cycle which forms important reducing agents necessary to produce energy.
However, intermediates of the TCA cycle, specifically citrate, can be exported out of the
mitochondria to the cytosol, converted to acetyl-CoA, and used for fatty acid synthesis
(Wakil et al., 1983). We believe that the increase in glycolytic and TCA cycle
intermediates seen in some of the BPA treatments may be an indication that BPA
increases glycolysis and the TCA cycle which leads to increased fatty acid synthesis.
This would be consistent with our finding that BPA may increase fatty acid synthase
expression, especially in the 1µM BPA treatment. To determine if BPA alters adipocyte
energy metabolism in a way that promotes de novo lipogenesis, a metabolic flux
experiment must be conducted. Metabolic flux profiling allows the tracking of labeled
isotopes into specific metabolic pathways
To determine if developmental exposure to BPA could possibly increase the
number of adipocyte precursors, we assayed the proliferation of mouse MSCs treated
with various concentrations of BPA. The data in Figure 3-3 show that all three BPA
treatments (1nM, 10nM, 1µM) significantly increased the proliferation of MSCs
compared to control (p=0.013, 0.032, 0.038, respectively) after 24 hours of treatment.
There is one less BPA treatment in this experiment due to spacing issue in the 96-well
plate; we omitted the 100nM because we were more interested in the low nanomolar
effects and comparing them to the 1µM treatment, which appeared to be having the
greatest impact. We saw similar effects after 48 hours of treatment, however the 10nM
39

estradiol treatment had now increased proliferation of the MSCs. There is evidence that
BPA may mediate its effects in two different ways. First, it may elicit a rapid response
via an interaction with ncmERs. It may also then elicit a slower, prolonged response via
an interaction with classical ERs (Alonso-Magdalena et al., 2005). Our data may
support these findings. The increase in proliferation seen in the first 24 hours only
occurs in cells treated with BPA (possibly via ncmERs). The increase seen after 48
hours also occurs in cells treated with estradiol, which would indicate a slower response
via the classical ERs. Once again, the cells treated with both BPA and estradiol did not
show any change in proliferation rate compared to control, which would further indicate
a competition between the molecules.
In summary, we have shown that BPA can increase the expression of important
inflammatory cytokines in adipose tissue. Inflammation plays an important role in a
number of the comorbidities associated with obesity, and BPA will only exacerbate the
vicious circle of inflammation and obesity. We also showed that BPA may increase
glycolysis and the TCA cycle which leads to enhanced de novo lipogenesis. These
findings go hand-in-hand with our finding that some concentrations of BPA increase
expression of fatty acid synthase. Finally, we also showed that BPA can increase the
proliferation of MSCs, thus increasing the number of adipocyte precursors and
increasing the fat potential later in life. These findings are interesting, however the
experiments do not represent the likely route of exposure in humans. To truly study the
effects that BPA has on adipose tissue, we must look at the effects it has in the context
of an organism via the most likely route of exposure, food and drink.
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CHAPTER IV
CHRONIC EXPOSURE TO BISPHENOL A IN JUVENILE MICE AND THE
EFFECTS ON ADIPOSE FUNCTION AND METABOLISM
Introduction
There have been some studies that have shown that BPA has adverse effects in
vivo, but at very high doses (Snyder et al., 2000, Kwon et al., 2000). BPA has been
detected in the urine of over 92% of the population, and higher BPA levels were
associated with cardiovascular disease and type II diabetes, but these results do not
prove causality (Melzer et al., 2010). A small number of studies have shown that BPA
affects the metabolism, insulin sensitivity, and adiposity of mice or rats exposed in utero
(Alonso-Magdalena et al., 2010, Somm et al., 2009). These findings are extremely
worrisome and show that BPA can have adverse effects on developing life. An analysis
of the 2003-04 NHANES data found that children ages 6-11 had the highest intake of
BPA based on bodyweight (Lakind and Naiman, 2008), and children obviously continue
to develop after birth and have important developmental periods through puberty. In
fact, this time period is a critical time for adipose tissue development in which both
adipocyte hyperplasia and hypertrophy can occur (Spalding et al., 2008). Therefore,
BPA exposure during early childhood through puberty could have similar effects to
those seen in perinatal exposure.
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There are a number of methods to administer BPA to mice (osmotic pump,
injection), but the most likely route of exposure in humans is food and drink. Once
ingested, BPA can be metabolized in the liver to the conjugated form Bisphenol Aglucuronide, but it can also be deconjugated throughout the body (Ginsberg and Rice,
2009, Nishikawa et al., 2010). Complex chemistry can take place in the body and,
therefore, adding BPA to the drinking water or food of the mice is the most relevant
method of exposure, however, this method makes measuring daily intake much more
difficult.
We added BPA to the drinking water of C57BL/6 and DBA/2J mice at three
concentrations (50nM, 500nM, and 5µM) as well as vehicle control starting at four
weeks of age. They were weighed weekly, and glucose tolerance tests were performed
at 8-9 weeks of age. Mice were sacrificed at 11 weeks of age and gonadal fat pads
were dissected for gene expression profiling, metabolomics analysis, and adipocyte
sizing. Blood was also collected for additional assays. We also had additional mice
that were treated with BPA for 6 more weeks on a high fat diet These mice were
sacrificed at 17 weeks of age and fat pads were dissected for the same analyses as the
other mice.
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Methods
Animals
C57BL/6J and DBA/2J mice were obtained from The Jackson Laboratory (Bar
Harbor, ME). The mice were housed and maintained in the Animal Facility and Office of
Laboratory Animal Care in Walters Life Sciences Building at the University of
Tennessee. Mice received a standard chow diet and water ad libitum. The housing
conditions were maintained at 70 ± 2 °F and 40-60% humidity. These stocks were used
to propagate offspring for this study. Sixty-four mice (32 males and 32 females) of each
strain were weaned at four weeks of age and randomized to a treatment group to avoid
litter effect. These mice were housed in special BPA-free polypropylene cages, and
water was provided in glass bottles to limit exposure to BPA or other estrogenic
compounds from the environment. BPA was administered to the mice via drinking
water, which was available ad libitum, at the concentrations of 50nM, 500nM, or 5µM.
The control groups received distilled ethanol, which was used to dissolve the BPA, at a
dose equal to the highest concentration of BPA. The mice were weighed weekly. At 11
weeks of age, mice were fasted for ~5 hours and sacrificed using CO2 asphyxiation and
cervical dislocation. The perigonadal fat pads were dissected and blood was collected
to measure fasting insulin levels. A portion of the fat pad was put in RNAlater for RNA
extraction, a portion was put in 4% paraformaldehyde for sectioning, and a portion was
snap frozen in liquid nitrogen for metabolomics analysis.

All protocols were approved

by the Institutional Animal Care and Use Committee at the University of Tennessee.
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Glucose Tolerance Tests
At between 8 and 9 weeks of age (14 and 15 for mice on high-fat diet), mice
were fasted for ~5 hours and injected intraperitoneally with glucose (1mg/g bw). Blood
was collected from the tail vein at 0, 15, 30, 60, and 120 mins after the injection and
measured using a glucometer. The measurements were averaged and plotted, and the
area under the curve (AUC) was determined.
RNA isolation
Total RNA was extracted from adipose tissue using the RNeasy™ Lipid Tissue
Mini Kit (Qiagen, Inc., Valencia, CA). The RNA quality and concentration were
assessed using the Nanodrop™ 2000 spectrophotometer (Thermo Scientific, Inc.) and
Experion RNA StdSens Chips on the Experion™ automated electrophoresis system
(Bio-Rad, Hercules, CA) to ensure excellent quality. RNA samples were stored at -80ºC
until needed.
Expression profiling
RNA from 24 male mice (6 500nM BPA and 6 Control per strain) was sent to
McGill University and Génome Québec Innovation Centre for gene expression profiling
using Illumina BeadArray™ technology. Total RNA (500ng) was amplified, synthesized
to cDNA, and hybridized to the MouseWG-6 v2 Expression BeadChip (Illumina, Inc.).
The BeadChip was then scanned using the iScan reader.
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Quantitative PCR
We reverse transcribed 500ng total RNA using the iScript™ cDNA
synthesis kit (Bio-Rad) which uses a modified MMLV-derived reverse transcriptase and
a combination of oligo(dT) and random hexamer primers. The relative expression of
transcripts coding for select genes were measured by quantitative real-time PCR
(QPCR) using a Quantitect primers on a CFX96™ Real-Time PCR Detection System
(Bio-Rad) and were normalized using the housekeeping gene Hprt. The genes
measured included Fasn, Lep, Pparg, Estrogen receptor alpha (Esr1), Adiponectin
(Adipoq), Estrogen related receptor gamma, (Esrrg), Paternally expressed gene 3
(Peg3), Serpine1, Calcium and integrin binding protein 2 (Cib2), Copine 8 (Cpne8), Gap
junction alpha 5 (Gja5), Lactate dehydrogenase (Ldhd), and Thrombospondin 2
(Thbs2). We quantified the expression using the QuantiTect SYBR Green PCR kit and
Primer Assays (Qiagen, Inc.), and relative gene expression was determine using the
∆∆Ct method with the Relative Expression Software Tool (Pfaffl et al., 2002).
Luminex analysis of adipokine levels
Adipose tissue concentrations of insulin, leptin, resistin, IL-6, TNFα, monocyte
chemotactic protein 1 (MCP-1), and plasminogen activator inhibitor 1 (PAI-1) were
analyzed by a multiplexed flow cytometric assay using a mouse serum adipokine
Milliplex® map kit (MADPK-71K, Millipore, Billerica, MA) on a Luminex® 200 system
(Luminex Inc., Austin, TX). The multiplexed assay had intra- and inter-assay variation
of < 4.5% and < 10.3%, respectively. All samples were analyzed in duplicate. The
45

assay was measured in pg/mL and normalized by measuring the total protein using a
BCA protein assay (Thermo Scientific) giving a final measurement of pg/µg total protein.
Serum insulin and adiponectin assays
Blood samples were collected at the time of sacrifice after a 5 hour fast and
centrifuged at 4ºC for 15 minutes at 2,000 x g. Serum aliquots were stored at -80ºC.
Fasting serum insulin levels were measured using a commercially available ultra
sensitive mouse insulin ELISA kit (Crystal Chem Inc., Downers Grove, IL). Serum
adiponectin levels were measured using a commercially available mouse adiponectin
enzyme immunoassay kit (SPI-bio Bertin Pharma, Montigny le Bretonneux, France).
Histological analysis of adipocyte size
A portion of the perigonadal fat pad was fixed for 24 hours in 4%
paraformaldehyde then washed in PBS. The samples were embedded in paraffin, cut
into 5µm sections, and stained with hematoxylin and eosin. Adipocyte size was
measured using a previously established method (Chen and Farese, 2002). Briefly, the
tissue sections were viewed at 10X magnification, and images were obtained. The
illumination of the images was adjusted using CellProfiler cell image analysis software
(www.cellprofiler.org). After the illumination was adjusted, the images were converted
to a binary image in ImageJ (NIH; rsbweb.nih.gov/ij/) using the following commands:
Gray Mode and Threshold. The binary images were further adjusted using Despeckle,
Watershed, Erode, and Paintbrush. The cross-sectional area of the adipocytes was
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measured using the “Analyze particles” command. Approximately 200 adipocytes per
mouse were measured.
Metabolomics
Approximately 15 mg of each adipose tissue sample was weighed into 1.5 mL
centrifuge tubes. Cold methanol (500 µL at -78oC) and the internal standards, tris (5 µL
of 4.7mM in H2O) and benzoic acid (5 µL of 1.7 mM in H2O), were added to each tube,
and then mixed by vortexing for 2 min. The samples were extracted for 30 min at 4oC on
ice prior to centrifugation (5 min, 13.2 rpm, 16.1 rcf, 4oC). Supernatants were split into
two autosampler vials each. One vial was placed directly in the autosampler for
analysis, and the other was frozen at -80oC for analysis in the opposite mode the
following day. High performance liquid chromatography (HPLC) was performed utilizing
a quaternary pump to generate a gradient for the elution of compounds from the
stationary phase. For all samples, 10 µL was injected onto the column via an
autosampler cooled to 4 °C. Eluent was directly introduced into the electrospray
ionization (ESI) chamber of the triple quadrupole mass spectrometer. Samples were
analyzed using selected reaction monitoring (SRM), and the scan time for each SRM
was 0.05 s with a scan width of 1 m/z. Raw files for each sample were first processed
using mzRock, and once the data set was narrowed, Xcalibur Quan Browser was used
to visualize and manually integrate metabolite peaks over a set time window.
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Statistical analysis
Differences in body weights were analyzed using repeated measures one-way
ANOVA and Tukey HSD post hoc test using R 2.12.0 or SYSTAT 13. Differences in
adiposity, glucose tolerance, adipose adipokines, serum insulin, serum adiponectin, and
adipocyte size were analyzed using a one-way ANOVA, and post hoc tests (t-test and
LSD) were performed once significance was determined. Results are shown as means
± SEM. A p-value < 0.05 was considered significant. Metabolomics data was also
analyzed using ANOVA, however a change of 1.5-fold or higher was considered
interesting and significant. All of the QPCR data was analyzed using REST which uses
a mathematical model based on the correction for exact PCR efficiencies and the mean
crossing point deviation between treatment groups and the control group. The
expression ratios are then tested for significance using a Pair Wise Fixed Reallocation
Randomisation Test©.
Statistical analysis of the Illumina microarray probe profile data was performed
using R 2.12.0. Data were processed based on detection p-values of at least 20 arrays
out of 24 arrays less than 0.05 using Genefilter package in Bioconductor, otherwise,
they were assumed to be low expression data and were filtered out. Quantile
normalization was applied to the data to make intensities consistent within each array.
The significance of gene expression was analyzed by ANOVA and empirical bayes
statistics (ebayes) using limma package. The differentially expressed genes with pvalue < 0.005 were identified.
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Results
Effect of BPA on body weight and adiposity
C57BL/6 and DBA/2J mice were exposed to BPA via drinking water after
weaning for seven weeks, and the mice were weighed weekly beginning at 4 weeks of
age. There was no difference in bodyweight between any of the treatments for females
of either strain (data not shown). However, there was a significant difference in the
body weight of male C57BL/6 mice treated with 50nM BPA compared to control starting
at 7 weeks of age that persisted until the time of sacrifice (Figure 4-1). Male C57BL/6
mice were 1.5-2.0g heavier (10 weeks of age: 500nM = 26.1g, control = 24.3, p<0.05)
from 7 weeks of age to the time of sacrifice. Male DBA/2J mice treated with 500nM
BPA were significantly heavier than control, but only near the end of the study at 10
weeks of age (500nM = 26g, control = 25g, p<0.05).
At the end of the study, gonadal fat pads were weighed and normalized to body
weight to determine adiposity. Again, there was no difference between any of the
treatments in females of either strain (data not shown). Adiposity was increased in the
500nM BPA treatment approximately 25% in the C57BL/6 males compared to control
(1.65 fat pad percentage in 500nM treatment compared to 1.32 in control, p=0.028)
(Figure 4-2). There was a smaller and less significant increase in adiposity of 8% in
DBA/2J male mice treated with 500nM BPA compared to control (2.26 fat pad
percentage in 500nM treatment compared to 2.09 in control, p=0.3). These data
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Figure 4-1. Effects of BPA on bodyweight in male mice. (A) C57BL/6 male mice
and (B) DBA/2J male mice. Mice were exposed to various doses of BPA via drinking
water. Results are means ± SEM. (*) p<0.05.
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Figure 4-2. Effects of BPA on adiposity in male mice. (A) C57BL/6 males and (B)
DBA/2J males. Gonadal fat pads were weighed and expressed as a percentage of
total body weight. Results are shown as means ± SEM. (*) p<0.05.
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suggest that the increase in body weight is associated with an increase in adipose
tissue.
Glucose tolerance tests
BPA has been shown to disrupt glucose homeostasis in pregnant mice as well as
their male offspring once they reached adulthood (Alonso-Magdalena et al., 2010).
Therefore, glucose tolerance tests were performed to determine if BPA has an effect on
insulin sensitivity and the ability to clear glucose. Due to the large of number of mice,
GTTs were performed over a two week span. There was a clear strain difference in the
sensitivity to this assay. Normally, following an i.p. injection of a glucose bolus, blood
glucose levels spike and then gradually decrease over the next 2 hours. We found that
the DBA/2J strain had a minimal spike and returned to pre-injection levels within 30
minutes. A previous study showed that DBA/2J mice have higher serum insulin levels
and generally lower blood glucose levels, so these results weren’t surprising (Alexander
et al., 2006). For this reason, we were unable to detect any difference between the
treatments for the DBA/2J mice (data not shown). The C57BL/6 mice had a more
traditional response to the glucose injection. Blood glucose measurements were
changed from mg/dL units to mmol/L and plotted. The area under the curve (AUC) was
determined to assay differences in glucose tolerance. We found that the AUC
measurements were higher for the mice exposed to BPA in both the males and females
of the C57BL/6 strain, however, only the 500nM treatment in the males was close to
being statistically significant (p=0.06) (Figure 4-3).
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Figure 4-3. Glucose tolerance test results for C57BL/6 mice treated with BPA. Males (A, B) treated with 50nM or
500nM BPA showed slower clearance rates compared to controls. The difference was not as great in females (C, D).
Results are shown as means ± SEM. (·) p<0.1.
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Serum insulin and adiponectin levels
We collected blood to measure fasting serum insulin levels to determine the
effect that BPA has on circulating insulin levels. Interestingly, we found no significant
differences in the males of either strain. However, we did see differences in the
females. All three treatments of BPA showed significantly higher serum insulin levels in
female C57BL/6 mice with the 5µM treatment having the greatest difference compared
to control (Figure 4-4). Surprisingly, we found the opposite result in female DBA2 mice.
All three treatments of BPA had significantly lower serum insulin levels compared to
controls, illustrating not only a physiological difference between the two strains but a
difference in the way each strain is affected by BPA. Due to limited resources, some of
the experiments and assays were only done for the specific groups that showed
differences in adiposity, i.e. the males of the 500nM BPA treated group and control
group. Measurement of serum adiponectin was one of these assays. We found that
the serum adiponectin levels were significantly (p=0.0012) lower in 500nM BPA group of
C57BL/6 males and were nearly significant (p=0.08) for the DBA/2J males (Figure 4-5).
Adipose adipokine profiles of BPA treated mice
The quantity of six adipokines were assayed in the adipose tissue of mice
treated with BPA using the mouse serum adipokine Milliplex® map kit on a Luminex®
200 system. The measurements for each adipokine were normalized using total protein
content and are expressed as pg/µg of total protein. We found much higher levels of
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Figure 4-4. Fasting serum insulin levels in mice treated with BPA. Mice were
fasted for ~5hrs and blood was drawn at sacrifice. Insulin was measured using a
commercially available ELISA kit. (·) p<0.1, (*) p<0.05, (**) p<0.01, (***) p<0.001.
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Figure 4-5. Serum adiponectin levels in males treated with BPA. Serum adiponectin
levels were determined using a commercially available EIA kit. (***) p<0.001.
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resistin compared to the other adipokines. There were no differences between
treatments for MCP-1, IL-6, TNFα, or resistin. There were also no extreme differences
between strains for any of the adipokines. The only adipokine that was significantly
altered by BPA was plasminogen activator inhibitor 1 (PAI-1). C57BL/6 males treated
with 50nM and 500nM had approximately twice the levels of PAI-1 compared to controls
(p=0.018, 0.012 for 50nM and 500nM, respectively) (Figure 4-6). We also found that
the 500nM dose of BPA slightly increased leptin in both C57BL/6 males and DBA/2J
males (data not shown), but the results were not significant.
Gene expression profiling and QPCR
Our results indicate that male mice exposed to 500nM BPA were significantly
fattier than their control counterparts. To identify changes in gene expression
associated with the increased adiposity, global gene expression profiling was performed
for these mice on the Illumina platform (Genome Quebec Innovation Center). Due to
the distribution of the data and the lack of a large set of expression changes, we were
unable to do FDR and extract q-values. Therefore, we were conservative in selecting
genes and used a p-value < 0.005. We found 95 genes differentially expressed in
C57BL/6 males and 71 genes differentially expressed in DBA/2J males. Of all these
genes, only 2 genes, Leptin and Heparan sulfate proteoglycan 2 (Hspg2), were
differentially expressed in both strains. Leptin was increased 1.45-fold and 1.41-fold
and Hspg2 was increased 1.25-fold and 1.18-fold in C57BL/6 and DBA/2J, respectively.
Generally, there were no large increases or decreases in expression that were
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Figure 4-6. Adipose levels of PAI-1 and Leptin in C57BL/6 males. Adipokine
levels were measured in adipose tissue using a Milliplex map kit and Luminex system.
Results shown as mean ± SEM. (*) p<0.05.
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statistically significant. The genes with the greatest significant change for each strain
are listed below (Table 4-1 and 4-2). There was a 2.56-fold decrease in Cytochrome
P450 2f2 for C57/BL6 treated compared to control and a 3.85-fold decrease in
Immunoglobulin kappa constant for DBA/2J. Transmembrane glycoprotein NMB
increased 1.7-fold in BPA treated C57BL/6 mice compared with control, and S100
calcium binding protein 8 increased 1.96-fold in DBA/2J mice.
We also conducted QPCR for a number of genes. We selected the adipogenic
and lipogenic genes, Pparg and Fasn. We also tested a number of other genes of
interest as well as some genes of interest identified from the initial array data. We
found no statistically significant difference in Fasn, Pparg, Esr1, Esrrg, or Adipoq for the
C57BL/6 males treated with BPA compared to control. There was a slight increase in
leptin expression, which matches with our array data, but the change was not
statistically significant (p=0.17) (Figure 4-7). For genes identified from the array data,
we confirmed statistically significant increases in Peg3 (2.25-fold increase, p=0.028),
Gja5 (1.75-fold increase, p=0.011), and Thbs2 (2.046-fold increase, p=0.005). We also
found a decrease in Ldhd expression (1.48-fold decrease) but the result weren’t
statistically significant (p= 0.09).
For the DBA/2J mice, there were also no significant changes in the expression of
Fasn, Pparg, Esr1, Essrg, or Adipoq. There was, however, a 1.40-fold increase in the
expression of Leptin (p=0.02) (Figure 4-8). For the genes chosen from the array data,
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Table 4-1. Top genes differentially expressed in C57BL/6 male mice treated
with 500nM BPA compared to control.

Gene symbol
Gpnmb
Mmp12
Sfrp5
Thbs2
Peg3
Emp3
Lep
Fbn1
Itih5
Myl4
Cyp2f2
Tst
Net1
Ldhd
Fos
Cyp2b10

Gene name
Transmembrane glycoprotein NMB
Matrix metalloproteinase 12
Secreted frizzled-related protein 5
Thrombospondin 2
Paternally expressed gene 3 protein
Epithelial membrane protein 3
Leptin
Fibrillin-1
Inter-alpha (globulin) inhibitor H5
Myosin light chain 4
Cytochrome P450 2F2
Thiosulfate sulfurtransferase
Neuroepithelial cell-transforming 1
Lactate dehydrogenase
FBJ osteosarcoma oncogene
Cytochrome P450 2B10

Fold change
1.7
1.69
1.66
1.64
1.62
1.57
1.45
1.45
1.44
1.4
-2.56
-1.89
-1.64
-1.54
-1.47
-1.35

p-value
0.0028
0.0012
0.0018
0.0070
0.0048
0.0030
0.0018
0.0020
0.0059
0.0031
0.0007
0.0023
0.0002
0.0029
0.0077
0.0072
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Table 4-2. Top genes differentially expressed in DBA/2J male mice treated
with 500nM BPA compared to control.

Gene symbol
S100a8
Cdkn1a
Dusp1
Klf6
Lep
Vldlr
Serpina1b
Eif5
Adap2
Osgin1
Igkc
Cxcl13
Igkv5
Faim3
Cyp2e1
Aebp1

Gene name
Fold change p-value
S100 calcium binding protein 8
1.96
0.0040
Cyclin-dependent kinase inhibitor 1
1.59
0.0050
Dual specificity protein phosphatase 1
1.52
0.0066
Krueppel-like factor 6
1.48
0.0015
Leptin
1.41
0.0033
Very low density lipoprotein receptor
1.35
0.0024
Serine peptidase inhibitor A1B
1.34
0.0033
Eukaryotic translation initiation factor 5
1.32
0.0060
ArfGAP w/ dual PH domains 2
1.3
0.0041
Oxidative stress induced growth factor 1
1.3
0.0035
Immunoglobulin kappa constant
-3.85
0.0013
CXC motif chemokine 13
-3.03
0.0002
Immunoglobulin kappa variable 5
-2.78
0.0011
Fas apoptotic inhibitory molecule 3
-1.49
0.0045
Cytochrome P450 2E1
-1.41
0.0011
Adipocyte enhancer binding protein 1
-1.39
0.0099
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Figure 4-7. QPCR results for selected genes in C57BL/6 male mice. Mice exposed
to 500nM BPA are compared to Controls. Results are expressed as expression ratios
determined using the ∆∆Ct method. (*)p<0.05, (**)p<0.01.
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Figure 4-8. QPCR results for selected genes in DBA/2J male mice. Mice
exposed to 500nM BPA are compared to Controls. Results are expressed as
expression ratios determined using the ∆∆Ct method. (*)p<0.05, (**)p<0.01.
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we confirmed significant changes in the expression of Cpne8 (1.39 decrease, p=0.018),
Ldhd (1.82 decrease, p=0.008), and Thbs2 (1.6 decrease, p=0.04).
Adipocyte size measurement
To determine if BPA exposure has an effect on adipocyte expansion, we used a
portion of the gonadal fat pad for histological analysis and measured average adipocyte
differences between mice exposed BPA versus control mice. We used a variation of
the method previously described (Chen and Farese, 2002) which uses computer image
analysis software to measure adipocyte size. The image conversion process results in
some small artifacts, therefore, we set a lower limit threshold that would allow us to
measure approximately 200 adipocytes per animal/slide. Once again, only the males
treated with 500nM or control were used for histological analysis. We found that the
males treated with 500nM had significantly larger adipocytes compared to control
(Figure 4-9). C57BL/6 males treated with 500nM BPA had an average adipocyte size of
10859 µm2 compared to 9143 µm2 in control (p=0.048). The DBA/2J males showed
similar results with an average adipocyte size of 13392 µm2 and 10081 µm2 in 500nM
BPA treatment and control, respectively (p=0.041).
Metabolomics
A portion of the gonadal fat pad was subjected to global metabolic profiling to
determine if in vivo exposure to BPA changes adipose tissue metabolism, which could
explain the changes in adiposity. We previously used this technique in adipose tissue
explants treated with BPA and found and trend for increased glycolytic and TCA cycle
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Figure 4-9. Effects of BPA on adipocyte size. Mice treated with 500nM BPA are
compared to control. Results are shown as means ± SEM. (*)p<0.05
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intermediates, indicating a change in adipose tissue energy metabolism. We expected
to see more subtle yet similar results for our in vivo treatment. We only used male
mice to measure the changes in metabolite levels since the changes in adiposity were
seen in males. Due to the variance in metabolite measurements from mouse to mouse,
we looked for metabolites with 1.5-fold difference between a BPA treatment and control.
We did not see many large changes in glycolytic metabolites or TCA cycle metabolites.
There was a decrease in the glycolytic metabolites fructose-6-phosphate (50nM = -1.89fold, 500nM = -2.35-fold) and phosphoenolpyruvate (5µM = -1.55-fold). Citrate is the
metabolite in the TCA cycle that can be shuttled out of the mitochondria and used for
fatty acid synthesis, and we saw a decrease in this metabolite as well (50nM = -2.12fold, 500nM = -2.01-fold) (Figure 4-10).

Discussion
We studied the effects that chronic exposure to BPA has on adipose tissue in an
organism using two different inbred strains of mice, C57BL/6 and DBA/2J. These are
the parental strains for the BXD recombinant inbred line, and both are routinely used in
cardiovascular and obesity studies (Campen et al., 2004, Gallou-Kabani et al., 2007).
We chose our doses of BPA based on previous research (Somm et al., 2009). Somm
and colleagues used a treatment of 1 mg/L BPA in the drinking water of pregnant
Sprague-Dawley rats and found increased birth weight, as well as increased adiposity
and adipogenesis in females at weaning. The highest concentration that we used, 5µM,
is 1.14 mg/L or approximately the same dose used in the Somm study. Because rats
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Figure 4-10. Glycolytic and TCA cycle intermediates levels in adipose tissue.
Fructose-6-phosphate and citrate were the two intermediates from glycolysis and
TCA cycle, respectively, with the greatest fold-change. Results are shown as
means ± SEM.
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are larger than mice, we chose to use the smaller, as well as more biologically relevant,
concentrations of 500nM and 50nM BPA. Based on an estimated daily intake of 6-7mL
water for each mice, we estimated that the daily intake of BPA for the 5µM, 500nM and
50nM treatment was 350µg/kg bw/day, 35µg/kg bw/day, and 3.5µg/kg bw/day,
respectively. This estimation was determined based on weekly water consumption and
does not account for spillage, therefore, the actual intake may be slightly lower than the
estimation. All three concentrations are lower than the No-observed-adverse-effectlevel (NOAEL) of 50mg/kg bw/day, and the low and middle concentration are below the
acceptable daily intake (ADI) for humans of 50µg/kg bw/day set by the EPA
(http://www.epa.gov/iris/subst/0356.htm).
We found no difference in bodyweight or adiposity for females exposed to BPA
compared to control. The results in Figure 4-1 and 4-2 show, however, that we did find
differences in males for both strains. In C57BL/6, males treated with lowest dose of
BPA were significantly heavier beginning at 7 weeks of age and continuing throughout
the study, but the only difference in adiposity occurred in the 500nM treatment. It’s
possible that the B6 males treated with 50nM BPA had greater fat gain in other depots,
however we only dissected gonadal fat pads which are representative of abdominal fat
in humans. DBA/2J males treated with 500nM were significantly heavier than controls
by the time of sacrifice. They also had increased adiposity, however, the results were
not statistically significant (p=0.08). There was a clear difference between the effects
seen in males and females. Because BPA is an endocrine disruptor and mimics
estrogen, it isn’t surprising to find that males and females may react differently to the
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treatments. It was also not surprising to find that the 500nM was the only treatment that
increased adiposity due to the lack of monotonic results in many other studies. Based
on these results, we decided to focus on males for a number of the other experiments,
and specifically the 500nM treatment of BPA.
Not surprisingly, we saw a significant difference in fasting blood glucose levels
between the sexes. What was surprising was the great difference between the strains.
The blood glucose levels in DBA/2J mice barely spiked after injection (data not shown),
indicating an ability in the DBA/2J strain to quickly regulate blood glucose levels.
C57/BL6 mice reacted as expected (Figure 4-3), and we found that male mice treated
with 50nM and 500nM cleared glucose from the blood slower than control, but the
results were no significant. We also measured fasting insulin levels to determine if BPA
may affect insulin synthesis and secretion. Surprisingly, we found significant difference
in females for both strains, but opposite results (Figure 4-4). C57BL/6 females had
higher fasting insulin levels in all treatments compared to control, but the DBA/2J
females had lower serum insulin levels in all treatments. There were no significant
differences in the males for either strain. These results, once again indicate a
physiologically difference between the two strains, and that the two strains may be
having different physiologically responses to BPA.
Low nanomolar concentrations of BPA have been shown to inhibit secretion of
adiponectin from adipose tissue (Hugo et al., 2008). We used an adiponectin EIA kit to
measure serum adiponectin levels in males treated with 500nM BPA or control. Our
findings are consistent with findings described by Hugo and colleagues (Hugo et al.,
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2008). Adiponectin levels were significantly lower in the serum of mice exposed to
500nM BPA (Figure 4-5). The decreases were greater and more significant in C57BL/6
mice than DBA/2J. We also measured the levels of other adipokines in the adipose
tissue of the male mice treated with BPA using the mouse serum adipokine Milliplex
xmap kit on the Luminex platform. While the Luminex system gave us a large amount
of data, we only found a significant difference in one analyte, PAI-1. C57BL/6 male
mice treated with 50nM or 500nM BPA had significantly higher levels of PAI-1
compared to control (Figure 4-6). PAI-1, or plasminogen activator inhibitor 1, is a serine
protease inhibitor, and higher serum levels of PAI-1 have been detected in patients with
coronary heart disease (Kohler and Grant, 2000). It has also been linked to obesity and
insulin resistance (Juhan-Vague and Alessi, 1997). PAI-1 is also known as Serpine1,
and the expression of many Serpines have been found to be elevated in fatty chickens
(Larry Cogburn, personal communication). Interestingly, the elevated PAI-1 levels were
found in the mice that were significantly heavier (50nM) and fatter (500nM) compared to
control.
We conducted expression profiling for the male mice treated with 500nM BPA
and control to try to identify the genes that were differentially expressed, which would
shed some insight on the molecular basis of BPA increasing adiposity. The list of
genes differentially expressed between treatments was fairly small, which prevented us
from performing FDR and extracting q-values. The mice were treated with lower doses
and at a less critical time of development compared to perinatal development, which
could explain more subtle changes in gene expression. We found that Leptin
70

expression was higher in treated which is consistent with our finding that the 500nM
treatment increased adiposity. There were some interesting genes identified. One of
particular interest was Peg3, or paternally expressed gene 3. We found that Peg3 was
increased 1.62-fold in C57BL/6 males treated with BPA (p=0.0048), and these results
were validated using QPCR (2.25-fold increase). A past study showed that a targeted
mutation in Peg3 led to increased body fat in mice and is a candidate gene for
regulation of fat content (Curley et al., 2005). It has also been shown to regulate energy
during gestation. Peg3 expression has also been shown to activate the TNF/NF-κB
pathway in kidney cells (Nogueira et al., 2009). Perhaps BPA increases Peg3
expression leading to disruption of energy homeostasis in adipose tissue, promoting
increased fat mass and inflammation. We also found a few Cytochrome P450 genes
that were down-regulated in the treated mice for both C57BL/6 and DBA/2J. We also
found that Serpinea1b expression was increased in DBA/2J males treated with BPA
which is consistent with the finding that Serpines have higher expression in fattier
chickens.
It is thought that obesity proceeds through both expansion of adipocytes and
proliferation of preadipocytes, however adipocyte hypertrophy occurs first (Spalding et
al., 2008). Adipocyte size is also positively correlated with insulin resistance and
inflammation (Skurk et al., 2007).Therefore, we believed that if BPA increased adiposity
and inflammation, we would see a difference in adipocyte size. We found that the
adipocytes of mice treated with 500nM BPA were slightly larger than those of mice
treated with the vehicle control (1.2x larger in C57BL6, 1.3x larger in DBA/2J), and
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these results were statistically significant (Figure 4-9). The changes were subtle and
not easily visible to the naked eye. There is evidence that smaller adipocytes are more
insulin sensitive than the larger adipocytes, and there is a greater population of smaller
adipocytes in leaner individuals (Skurk et al., 2007). Due to the image conversion
method, we were only able to measure the 200 largest cells per frame and could not
measure the smaller adipocytes.
The changes in metabolite levels in mice exposed to BPA compared to control
were more subtle than the changes observed in the adipose tissue explants, which was
not surprising. However, what was somewhat surprising was to find that the levels of
some glycolytic and TCA cycle intermediates were lower in treated mice, which was the
opposite of our findings in the ex vivo study (Figure 4-11). Fructose-6-phosphate, an
intermediate of glycolysis, was decreased in mice treated with 50nM and 500nM BPA
(1.89-fold and 2.35-fold change, respectively. Citrate, the TCA cycle intermediate that
is used in lipogenesis, was also decreased for these treatments (2.12-fold and 2.01-fold
change, respectively). A low metabolite pool can indicate that the metabolic pathway is
decreased or it could mean that the metabolic pathway is so active that the metabolites
do not have a chance to form a pool before being used in another pathway. It’s
possible that the metabolites of glycolysis and the TCA cycle were able to pool in the
adipose tissue explants, however in the live mice the metabolites get used by another
pathway much more rapidly. If this is the case, then this would indicate that glycolysis
and the TCA cycle are still increased, and perhaps citrate is being shuttled out of the
mitochondria rapidly to form acetyl-CoA and undergo lipogenesis (Figure 4-11).
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Figure 4-11. Diagram of the TCA cycle and citrate shuttle. Pyruvate from
glycolysis enters the mitochondria to enter the TCA cycle. An intermediate,
citrate can be shuttled to the cytosol to be converted to acetyl-CoA and begin
fatty acid synthesis (Garrett and Grisham. Biochemistry. 2nd Ed. 1999).

Figure 4-11. Diagram of the TCA cycle and citrate shuttle. Pyruvate from glycolysis
enters the mitochondria to enter the TCA cycle. An intermediate, citrate can be shuttled
to the cytosol to be converted to acetyl-CoA and begin fatty acid synthesis (Garrett and
Grisham. Biochemistry. 2nd Ed. 1999).
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Conclusion
There are definitely genetic and phenotypic differences between sex and strain,
and these differences appear to affect the impact that BPA has on an individual. The
BPA studies to date for adiposity are few, and almost all have focused on the effects of
in utero exposure. We essentially modeled childhood exposure, independent of any
“programming” that may occur during embryonic development. We showed a modest
but significant increase in fatness with consumption of a reasonable level of BPA over a
seven week period. The bodyweight and adiposity of the males were increased for both
C57BL/6 and DBA/2J treated with BPA. The serum insulin levels were unchanged in
the males but were changed in females for both strains, however BPA had an opposite
effect in each strain. A different set of genes were differentially expressed between
C57BL/6 and DBA/2J. The adipocytes were slightly larger for both strains exposed to
BPA, and some glycolytic and TCA cycle intermediates were lower in treated indicating
that those metabolic pathways may have been more active. Taken together these data
indicate that BPA disrupts energy homeostasis and gene expression in adipose tissue
in way that promotes weight gain, however the severity of its action is unclear. Our
results imply that BPA consumed in children may contribute to childhood obesity by
promoting adipocyte expansion, independent of any developmental effects of BPA. In
conclusion, we showed that BPA exposure below the ADI may increase adiposity and
promote weight gain, and although the effects are probably not as severe as those that
occur from gestational and perinatal exposure, they can further exacerbate the effects
incurred in utero.
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CHAPTER V
FUTURE STUDIES
We have demonstrated that BPA can disrupt adipose tissue metabolism, gene
expression, and endocrine function in a way that promotes weight gain, however, the
effects were modest and not dose-dependent. These non-monotonic results are
consistent with other results commonly seen in studies of endocrine disrupting
chemicals (Grun and Blumberg, 2009a, Vandenberg et al., 2009). The method of
delivery was also a possible source of variability. Controlling the dosage is much more
difficult when administering orally via drinking water due to the variability of water intake
between animals. Our estimates of daily intake are based on daily water intake per
cage and don’t account for spillage, so it is possible that some of the treatments were
lower from cage to cage. However, this is necessary to replicate the most likely route of
exposure in humans.
A future study that is planned is to determine if BPA treatment exacerbates
weight gain and the inflammatory effects of a high fat diet. We conducted a preliminary
experiment that studied the effect that a high fat diet combined with BPA exposure has
on body weight and adiposity, and these results can be found in the appendix of this
thesis. The typical consumption pattern in the United States would be that of a high
dietary fat intake coupled with significant BPA exposure, and it is quite possible that
these two things in concert have led to the obesity epidemic.
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There are also plans to conduct a study in which we will treat pregnant mice with
BPA via drinking water and continue treatment in the pups after birth. Our future in vivo
BPA studies should focus on one strain, C57BL/6. This strain appeared to be more
sensitive to BPA than the DBA/2J strain and is commonly used in obesity studies
(Gallou-Kabani et al., 2007, Schreyer et al., 1998). Humans are commonly exposed to
low nanomolar doses, therefore, we should use a low nanomolar dose as well. In the
next study, we should replace the 5µM dose with a 5nM dose. For these future studies,
along with the measurement we performed previously (body weight, adiposity,
adipocyte size, etc.), we should measure fasting glucose and the circulating levels of
adipokines rather than adipokine levels in the tissue. We should also examine the
effects that BPA has on the liver and pancreas. A study that combines perinatal BPA
exposure and continues treatment to adolescence would best represent the level of
exposure to BPA in the US, especially those in lower income environments. Those in
lower income communities are most likely not educated on the potential dangers of
BPA. A study that exposed mice to low levels of BPA during gestational and perinatal
development through adulthood would likely represent the levels of exposure for a large
portion of humans.
We found that BPA did not alter expression of the adipogenic regulator, PPARγ,
however, it is possible that BPA may enhance the activity of PPARγ. A mutation in the
this gene that results in constitutively active PPARγ results in extreme obesity, and
there is evidence that some endocrine disruptors affect PPARγ signaling (Ristow et al.,
1998, Grun et al., 2006). It is possible that the increase in adiposity observed in our
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study may be due to enhanced activity of PPARγ. To study the effects that BPA has on
PPARγ activity, we would use a PPARγ response element plasmid. Briefly, PPRE X3TK-luc plasmid would be transfected into differentiated 3T3-L1s, or another cell line that
adequately expresses PPARγ. The cells would then be treated with doses of BPA
ranging from 1nM to 1µM. If BPA enhances the activity of PPARγ, the transcription
factor will bind the PPRE resulting in luciferase expression and a light signal.
Rosiglitazone would be used as a positive control, and the expression of luciferase
would be proportional to the PPARγ activity. This experiment would allow us to
determine if biologically relevant concentrations of BPA may promote adipogenesis
through activation of PPARγ.
The metabolomic experiments we conducted allowed us to measure pools of
metabolites in adipose tissue and detect changes that may be a result of BPA
treatment. While these experiments provide insight to the metabolic changes that occur
as a result of BPA, they only provide a snapshot of the metabolism at the time of
sacrifice. To determine the rate at which these metabolites are being used or produced,
we must conduct a metabolic flux analysis. This type of experiment can be done using
adherent mammalian cells, and we would use differentiated 3T3-L1s (Yuan et al.,
2008). Cells are grown in unlabeled media for a period of time before being switched to
media containing C-13 labeled glucose or glutamine. Metabolites are extracted from
the cells at various time points from 0 mins to 4 hrs. Metabolites are measured using
LC-MS/MS to measure the rate that a certain metabolite is produced. In our
experiment, cells would be treated with 1nM, 10nM, 1µM, or control (EtOH) for 24 hrs
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before being switched to the labeled media. The treatment would continue during the
labeled media switch. This would allow us to definitively determine if the increase or
decrease in glycolytic and TCA cycle metabolites is a result of changes in these
metabolic pathways, and if citrate is being funneled into de novo lipogenesis.
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Effects of Bisphenol A on Body Weight and Adiposity in Combination
with a High Fat Diet
We performed a small preliminary experiment to study the effect that BPA has in
combination with a high fat diet. There were 8 C57BL/6 mice (4 males and 4 females)
and 8 DBA/2J mice were exposed to 5µM BPA beginning at 4 weeks of age, as well as
8 control mice per strain. At 11 weeks of age, all mice were switched from standard
chow to a high fat diet (58% fat). Mice were weighed weekly and sacrificed at 17 weeks
of age. We dissected gonadal fat pads to assess adiposity. We found that both
C57BL/6 males and females treated with BPA were significantly heavier compared to
control by the end of the study (37.4g vs 33.2g in males, p=0.035; 28.7g vs 24.8g in
females, p=0.014) (Figure A-1). There was no significant difference in the DBA/2J mice.
We also found that both C57BL/6 males and females treated with BPA were fattier
(6.8% vs 5.94% in males, p=0.065; 4.21% vs 2.99%, p=0.074) (Figure A-2). The
C57BL/6 males exposed to BPA also had significantly higher serum insulin levels
compared to controls, but there was no difference in females (Figure A-3). These data
suggest that BPA may exacerbate the effects of a high fat diet and further experiments
and analysis are necessary.
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Figure A-1. Bodyweight data of mice on a high fat diet treated with
BPA. C57BL/6 mice (above) and DBA/2J mice (below) were treated with
5uM BPA or control from 4 weeks of age to 17 weeks of age. They were
switched to a high fat diet at 12 weeks of age. Results are means ± SEM.
(*)p<0.05.
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Figure A-2. Effects of BPA on adiposity in mice on a high fat diet. Gonadal fat
pads were dissected from C57BL/6 (above) and DBA/2J (below) and divided by total
body weight as a measurement of adiposity. Results are means ± SEM. (·)p<0.1.
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Figure A-3. Serum insulin levels in mice on a high fat diet treated with BPA.
Insulin levels are higher in C57BL/6 males treated with BPA and lower in DBA/2J males
treated with BPA. Results are means ± SEM. (*)p<0.05, (**)p<0.01.
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Table A-1. Genes significantly changed in C57BL/6 males treated with 500nM
BPA compared to control.
Gene symbol

Gene name

Fold change

p‐value

GPNMB

glycoprotein (transmembrane) nmb (Gpnmb),
mRNA.
matrix metallopeptidase 12 (Mmp12), mRNA.

1.703

0.00279

1.686

0.00119

1.655

0.00184

PEG3

secreted frizzled‐related sequence protein 5 (Sfrp5),
mRNA.
paternally expressed 3 (Peg3), mRNA.

1.620

0.00481

EMP3

epithelial membrane protein 3 (Emp3), mRNA.

1.568

0.00299

HIST1H2AI

histone cluster 1, H2ai (Hist1h2ai), mRNA.

1.491

0.00262

LEP

leptin (Lep), mRNA.

1.449

0.00178

MMP12
SFRP5

1.447

0.00204

MYL4

FBN1
myosin, light polypeptide 4 (Myl4), mRNA.

1.402

0.00309

SLC11A1

solute carrier family 11 (proton‐coupled divalent
metal ion transporters), member 1 (Slc11a1), mRNA.
eukaryotic translation initiation factor 4E member 3
(Eif4e3), mRNA.
reticulon 2 (Z‐band associated protein) (Rtn2),
transcript variant B, mRNA.
sema domain, immunoglobulin domain (Ig), and GPI
membrane anchor, (semaphorin) 7A (Sema7a),
mRNA.
histone cluster 1, H2an (Hist1h2an), mRNA.

1.387

0.00485

1.365

0.00397

1.362

2.00E‐04

1.358

0.00254

EIF4E3
RTN2
SEMA7A

HIST1H2AN

1.354

0.00215

RIKEN cDNA 9130211I03 gene (9130211I03Rik),
mRNA.
paralemmin (Palm), mRNA.

1.351

0.00213

1.345

0.00199

1.314

0.00134

1.309

0.00477

MYO1G

gap junction membrane channel protein alpha 5
(Gja5), mRNA.
reticulocalbin 3, EF‐hand calcium binding domain
(Rcn3), mRNA.
myosin IG (Myo1g), mRNA.

1.305

0.0011

PFTK1

PFTAIRE protein kinase 1 (Pftk1), mRNA.

1.303

0.00242

ADSSL1

adenylosuccinate synthetase like 1 (Adssl1), mRNA.

1.296

0.00393

MFSD7A

major facilitator superfamily domain containing 7A
(Mfsd7a), mRNA.
solute carrier family 25 (mitochondrial thiamine
pyrophosphate carrier), member 19 (Slc25a19),
nuclear gene encoding mitochondrial protein, mRNA.
proline arginine‐rich end leucine‐rich repeat (Prelp),
mRNA.
hairy/enhancer‐of‐split related with YRPW motif 1
(Hey1), mRNA.
transmembrane protein 160 (Tmem160), mRNA.

1.281

0.0019

1.277

0.00341

1.275

0.00085

1.275

0.00234

1.269

0.00348

1.267

0.00193

PQLC3

ADP‐ribosylation factor GTPase activating protein 2
(Arfgap2), mRNA.
PQ loop repeat containing (Pqlc3), mRNA.

1.264

0.00478

PLD3

phospholipase D family, member 3 (Pld3), mRNA.

1.259

0.00112

9130211I03RIK
PALM
GJA5
RCN3

SLC25A19

PRELP
HEY1
TMEM160
ARFGAP2
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Table A-1 (continued)
Gene symbol

Gene name

Fold change

p‐value

CSNK1G2

casein kinase 1, gamma 2 (Csnk1g2), mRNA.

1.249

0.00204

IL27RA

interleukin 27 receptor, alpha (Il27ra), mRNA.

1.247

0.002

UCHL1

ubiquitin carboxy‐terminal hydrolase L1 (Uchl1),
mRNA.
glycolipid transfer protein (Gltp), mRNA.

1.244

0.0032

1.243

0.00478

RIKEN cDNA 2410008K03 gene (2410008K03Rik),
mRNA.

1.241

0.00062

1.234

0.00438

1.226

0.00026

1.225

0.00355

1.222

8.00E‐05

1.218

0.00479

1.216

0.00152

1.211

0.00037

1.210

0.00147

1.208

0.00114

1.207

0.00317

1.198

0.00219

1.193

0.00436

1.185

0.00374

1.180

0.00277

1.179

0.00126

GLTP
2410008K03RIK
FOXO1
1810008A18RIK
KIF1C
CAMK1
NECAP2

RIKEN cDNA 1810008A18 gene (1810008A18Rik),
mRNA.
kinesin family member 1C (Kif1c), mRNA.
calcium/calmodulin‐dependent protein kinase I
(Camk1), mRNA.
NECAP endocytosis associated 2 (Necap2), mRNA.

PEA15
RUSC2
PACS2
MARVELD1
HPCAL1
ESAM

RUN and SH3 domain containing 2 (Rusc2),
transcript variant 1, mRNA.
phosphofurin acidic cluster sorting protein 2 (Pacs2),
mRNA.
PREDICTED: MARVEL (membrane‐associating)
domain containing 1 (Marveld1), misc RNA.
hippocalcin‐like 1 (Hpcal1), mRNA.
endothelial cell‐specific adhesion molecule (Esam),
mRNA.

D930038O18RIK
D330027H18RIK

PREDICTED: RIKEN cDNA D330027H18 gene
(D330027H18Rik), mRNA.

LHX6
LEPRE1

leprecan 1 (Lepre1), transcript variant 3, mRNA.

NFKB2

1.176

0.0038

2810043G13RIK

1.174

0.00468

1.172

0.00178

1.171

0.00489

FLOT1

ROD1 regulator of differentiation 1 (S. pombe)
(Rod1), transcript variant 1, mRNA.
zinc finger and BTB domain containing 3 (Zbtb3),
mRNA.
flotillin 1 (Flot1), mRNA.

1.169

0.0017

CTSS

cathepsin S (Ctss), mRNA.

1.159

0.00464

ABCA3

ATP‐binding cassette, sub‐family A (ABC1), member
3 (Abca3), transcript variant 1, mRNA.
RIKEN cDNA 2410127L17 gene (2410127L17Rik),
mRNA.
basic leucine zipper transcription factor, ATF‐like 3
(Batf3), mRNA.
zinc finger protein 473 (Zfp473), mRNA.

1.157

0.0046

1.150

0.00172

1.150

0.00477

ROD1
ZBTB3

2410127L17RIK
BATF3
ZFP473
STRN
RBMY1A1

RNA binding motif protein, Y chromosome, family 1

1.138

0.00375

1.120

0.00463

‐1.125

0.00453
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Table A-1 (continued)
Gene symbol

Gene name

NDUFA4

NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 4 (Ndufa4), mRNA.
dual specificity phosphatase 6 (Dusp6), mRNA.

DUSP6
LOC100046744

PREDICTED: similar to Serine/arginine repetitive
matrix protein 2 (LOC100046744), mRNA.

4930487N19RIK

Fold change

p‐value

‐1.148

0.00069

‐1.149

0.00195

‐1.153

0.00054

‐1.157

0.00319

RBM3

RNA binding motif protein 3 (Rbm3), mRNA.

‐1.160

0.00184

CAMK2D

calcium/calmodulin‐dependent protein kinase II,
delta (Camk2d), transcript variant 2, mRNA.
camello‐like 1 (Cml1), mRNA.

‐1.173

0.00484

‐1.179

0.00323

MYOG

myogenin (Myog), mRNA.

‐1.188

0.00142

BAG4

BCL2‐associated athanogene 4 (Bag4), mRNA.

‐1.206

0.00245

‐1.223

0.00269

‐1.224

0.00493

‐1.227

0.00425

CML1

5530401J07RIK
RAF1
MYO1B

myosin IB (Myo1b), mRNA.

ZFAND6

zinc finger, AN1‐type domain 6 (Zfand6), mRNA.

‐1.228

0.0049

UQCRC2

‐1.239

7.00E‐04

NKG7

ubiquinol cytochrome c reductase core protein 2
(Uqcrc2), mRNA.
natural killer cell group 7 sequence (Nkg7), mRNA.

‐1.240

0.00341

DCXR

dicarbonyl L‐xylulose reductase (Dcxr), mRNA.

‐1.244

0.00412

PDE4DIP

phosphodiesterase 4D interacting protein
(myomegalin) (Pde4dip), transcript variant 1, mRNA.
carbonic anhydrase 1 (Car1), transcript variant 1,
mRNA.
tetratricopeptide repeat domain 33 (Ttc33), mRNA.

‐1.266

0.00199

‐1.271

0.00403

‐1.276

0.00439

‐1.287

0.00205

‐1.298

0.00297

SCL33870.2_144

‐1.299

4.00E‐05

4631423B10RIK

‐1.308

0.00021

‐1.312

0.00252

CAR1
TTC33
PRDX3
MAOB

RSPO3
LUC7L2

monoamine oxidase B (Maob), nuclear gene
encoding mitochondrial protein, mRNA.

R‐spondin 3 homolog (Xenopus laevis) (Rspo3),
mRNA.
LUC7‐like 2 (S. cerevisiae) (Luc7l2), mRNA.

SCL000408.1_6
SCL33870.2_144
NET1
LDHD
NET1
TST
CYP2F2

neuroepithelial cell transforming gene 1 (Net1),
transcript variant 1, mRNA.
lactate dehydrogenase D (Ldhd), nuclear gene
encoding mitochondrial protein, mRNA.
neuroepithelial cell transforming gene 1 (Net1),
transcript variant 2, mRNA.
thiosulfate sulfurtransferase, mitochondrial (Tst),
nuclear gene encoding mitochondrial protein, mRNA.
cytochrome P450, family 2, subfamily f, polypeptide
2 (Cyp2f2), mRNA.

‐1.319

0.00177

‐1.371

0.00099

‐1.436

4.00E‐04

‐1.506

0.00028

‐1.545

0.00287

‐1.636

0.00015

‐1.897

0.00231

‐2.558

7.00E‐04
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Table A-2. Genes significantly changed in DBA/2J males treated with 500nM BPA
compared to control
Gene symbol

Gene name

Fold change

p‐value

S100A8

S100 calcium binding protein A8 (calgranulin A) (S100a8), mRNA.

1.963

0.00401

KLF6

Kruppel‐like factor 6 (Klf6), mRNA.

1.475

0.00154

LEP

leptin (Lep), mRNA.

1.411

0.00329

1.402

5.00E‐05

2310036D22RIK
VLDLR

very low density lipoprotein receptor (Vldlr), mRNA.

SCL0002315.1_12
SERPINA1B

1.345

0.0024

1.342

0.00198

1.337

0.00331

HIST2H3C1

serine (or cysteine) preptidase inhibitor, clade A, member 1b (Serpina1b),
mRNA.
histone cluster 2, H3c1 (Hist2h3c1), transcript variant 1, mRNA.

1.306

0.00474

ADAP2

ArfGAP with dual PH domains 2 (Adap2), mRNA.

1.305

0.00414

OSGIN1

oxidative stress induced growth inhibitor 1 (Osgin1), mRNA.

1.301

0.00347

FABP9

fatty acid binding protein 9, testis (Fabp9), mRNA.

1.287

0.00303

IQGAP1

1.286

0.00076

NFIC

1.256

0.00491

1.255

0.00331

1.243

0.00362

JUN

Jun oncogene (Jun), mRNA.

C130073O12RIK
CCDC53

coiled‐coil domain containing 53 (Ccdc53), mRNA.

1.238

0.0038

SERPINA1A

serine (or cysteine) peptidase inhibitor, clade A, member 1a (Serpina1a),
mRNA.
potassium voltage gated channel, Shab‐related subfamily, member 1
(Kcnb1), mRNA.
phosphatidylinositol 4‐kinase type 2 beta (Pi4k2b), transcript variant 2,
mRNA.
blocked early in transport 1 homolog (S. cerevisiae) (Bet1), mRNA.

1.235

3.00E‐04

1.233

0.00304

1.226

4.00E‐05

1.221

0.00118

1500034J01RI
K
SMEK2

PREDICTED: RIKEN cDNA 1500034J01 gene (1500034J01Rik), mRNA.

1.213

0.0018

SMEK homolog 2, suppressor of mek1 (Dictyostelium) (Smek2), mRNA.

1.211

0.0034

PRKRIR

1.207

0.00393

IGSF21

protein‐kinase, interferon‐inducible double stranded RNA dependent
inhibitor, repressor of (P58 repressor) (Prkrir), mRNA.
immunoglobin superfamily, member 21 (Igsf21), mRNA.

1.206

0.00052

IMPAD1

inositol monophosphatase domain containing 1 (Impad1), mRNA.

1.203

0.00288

1.202

0.00024

1.197

0.00479

KCNB1
PI4K2B
BET1

TTC14
N6AMT1

N‐6 adenine‐specific DNA methyltransferase 1 (putative) (N6amt1), mRNA.

CALU

calumenin (Calu), transcript variant 2, mRNA.

1.191

0.00491

NACC2

1.184

0.00256

2610524H06RI
K
HSPG2

nucleus accumbens associated 2, BEN and BTB (POZ) domain containing
(Nacc2), transcript variant 1, mRNA.
RIKEN cDNA 2610524H06 gene (2610524H06Rik), mRNA.

1.183

0.00304

PREDICTED: perlecan (heparan sulfate proteoglycan 2) (Hspg2), mRNA.

1.179

0.00348

HAS2

hyaluronan synthase 2 (Has2), mRNA.

1.170

0.00407

OLFR1085

olfactory receptor 1085 (Olfr1085), mRNA.

1.165

0.00206

OPN1MW

opsin 1 (cone pigments), medium‐wave‐sensitive (color blindness, deutan)
(Opn1mw), mRNA.
LY6/PLAUR domain containing 6B (Lypd6b), mRNA.

1.161

0.00285

1.153

0.00482

LYPD6B
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Table A-2 (continued)
Gene symbol

Gene name

Fold change

p‐value

LRSAM1

leucine rich repeat and sterile alpha motif containing 1 (Lrsam1), mRNA.

1.145

0.00257

IGHV1S20_K02153_IG_HEAVY_VARIABLE_1S20_37

1.142

0.00238

AMIGO3

1.137

0.00162

LOC380854

1.110

0.00401

4933406P04RIK

‐1.113

0.00416

‐1.128

0.00206

‐1.135

0.00483

‐1.139

0.00198

LOC10004469
8
AOC2

adhesion molecule with Ig like domain 3 (Amigo3), mRNA.

PREDICTED: similar to Unknown (protein for MGC:117841) (LOC100044698),
mRNA.
amine oxidase, copper containing 2 (retina‐specific) (Aoc2), mRNA.

FGD6
6030441H18RIK

‐1.143

0.00185

TCEAL6

transcription elongation factor A (SII)‐like 6 (Tceal6), mRNA.

‐1.149

0.0045

PSMB4

proteasome (prosome, macropain) subunit, beta type 4 (Psmb4), mRNA.

‐1.155

0.00475

1810009O10RIK

‐1.162

0.00377

MRAS

muscle and microspikes RAS (Mras), mRNA.

‐1.177

0.00219

MTMR11

myotubularin related protein 11 (Mtmr11), mRNA.

‐1.180

0.00424

PHF13

PHD finger protein 13 (Phf13), mRNA.

‐1.189

0.00125

KLC2

kinesin light chain 2 (Klc2), mRNA.

‐1.193

0.00193

MUP3

major urinary protein 3 (Mup3), mRNA.

‐1.204

0.00359

‐1.207

0.0026

‐1.208

0.00445

‐1.209

0.00349

‐1.213

0.00217

BC039093
AFG3L1

AFG3(ATPase family gene 3)‐like 1 (yeast) (Afg3l1), mRNA.

E030027L17
GIMAP7

GTPase, IMAP family member 7 (Gimap7), mRNA.

BC030499

cDNA sequence BC030499 (BC030499), mRNA.

‐1.221

0.00219

FBXL6

F‐box and leucine‐rich repeat protein 6 (Fbxl6), mRNA.

‐1.223

0.00333

TRF

transferrin (Trf), mRNA.

‐1.236

0.00222

LOC10004781
5
FCGRT

PREDICTED: similar to CD79A antigen (immunoglobulin‐associated alpha)
(LOC100047815), mRNA.
Fc receptor, IgG, alpha chain transporter (Fcgrt), mRNA.

‐1.251

0.00276

‐1.254

0.00427

RHBDL1

rhomboid, veinlet‐like 1 (Drosophila) (Rhbdl1), mRNA.

‐1.267

0.00072

CYP2E1

cytochrome P450, family 2, subfamily e, polypeptide 1 (Cyp2e1), mRNA.

‐1.418

0.00107

FAIM3

Fas apoptotic inhibitory molecule 3 (Faim3), mRNA.

‐1.503

0.00452

‐2.553

0.00128

PREDICTED: similar to NF‐180 (LOC100047899), mRNA.

‐2.578

0.00235

PREDICTED: immunoglobulin kappa chain variable 5 (V5 family) (Igk‐V5),
mRNA.

‐2.761

0.00108

CXCL13

‐3.059

2.00E‐04

IGK‐C

‐3.918

0.00128

‐4.252

0.0011

LOC381774
LOC10004789
9
IGK‐V5

LOC10004762
8

PREDICTED: similar to Chain L, Structural Basis Of Antigen Mimicry In A
Clinically Relevant Melanoma Antigen System, transcript variant 3
(LOC100047628), mRNA.
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